UNITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Form 10-K
|
|
|
þ
|
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
|
|
For the fiscal year ended October 31,
2010
|
or
|
o
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
|
|
For the transition period
from to
|
Commission file number: 0-13907
Synovis Life Technologies,
Inc.
(Exact name of Registrant as
specified in its charter)
|
|
|
Minnesota
|
|
41-1526554
|
(State of
Incorporation)
|
|
(I.R.S. Employer Identification
No.)
|
2575 University Avenue W.,
St. Paul, Minnesota
55114-1024
(Address of principal executive
offices)
Telephone Number:
(651) 796-7300
Securities Registered Pursuant to Section 12(b) of the
Act:
|
|
|
Title of Each Class:
|
|
Name on Each Exchange on Which Registered:
|
|
Common Stock, $.01 par value
|
|
|
Common Stock Purchase Rights
|
|
The Nasdaq Stock Market
|
Securities Registered Pursuant to Section 12(g) of the
Act: None
Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities
Act.
Yes o
No þ
Indicate by check mark if the registrant is not required to file
reports pursuant to Section 13 or Section 15(d) of the
Exchange Act.
Yes o
No þ
Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of
the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes þ No o
Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any,
every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of
Regulation S-T
(§ 232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant
was required to submit and post such files).
Yes o No o
Indicate by check mark if disclosure of delinquent filers
pursuant to Item 405 of
Regulation S-K
is not contained herein, and will not be contained, to the best
of registrants knowledge, in definitive proxy or
information statements incorporated by reference in
Part III of this
Form 10-K
or any amendment to this
Form 10-K. þ
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See the definitions of
large accelerated filer, accelerated
filer and smaller reporting company in
Rule 12b-2
of the Exchange Act. (Check one):
|
|
|
|
|
|
|
Large accelerated filer o
|
|
Accelerated filer þ
|
|
Non-accelerated filer o
(Do not check if a smaller reporting company)
|
|
Smaller reporting company o
|
Indicate by check mark whether the registrant is a shell company
(as defined in
Rule 12b-2
of the Exchange Act).
Yes o
No þ
As of April 30, 2010, the last business day of the
registrants second quarter of fiscal 2010,
11,298,157 shares of Common Stock of the registrant were
outstanding, and the aggregate market value of the
registrants outstanding Common Stock (based upon the
closing price of the Common Stock on that date as reported by
the Nasdaq Global Market), excluding outstanding shares owned
beneficially by executive officers, directors and affiliates,
was approximately $160,085,000.
As of December 20, 2010, 11,258,033 shares of the
registrants Common Stock were outstanding.
Part III of this Annual Report on
Form 10-K
incorporates by reference (to the extent specific sections are
referred to herein) information from the registrants Proxy
Statement for its Annual Meeting of Shareholders to be held
March 3, 2011 (the 2011 Proxy Statement).
TABLE OF CONTENTS
Except where the context otherwise requires, references in this
Annual Report on
Form 10-K
to Synovis, Company, we, and
our are to Synovis Life Technologies, Inc. and its
subsidiaries collectively.
Registered
Trademarks:
APEX
processing®,
Dura-Guard®,
Flo-Rester®,
Flo-Thru
Flo-Rester®,
Flo-thru Intraluminal
Shunt®,
Flow
Coupler®,
Neurotube®,
OrthAdapt®,
Peri-Guard®,
Peri-Strips®,
Peri-Strips
Dry®,
Supple
Peri-Guard®,
Synovis®,
Ultifix®,
Ultister®,
Unite®,
Vascu-Guard®
and
Veritas®,
are registered trademarks of the Company.
Forward-Looking
Statements
Certain statements contained in this Annual Report on
Form 10-K
are forward looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. For this purpose, any statements contained in this
Form 10-K
that are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the foregoing,
words such as may, should,
will, expect, believe,
anticipate, estimate,
continue or the negative or other variations thereof
or comparable terminology are intended to identify
forward-looking statements. All forward-looking statements in
this document are based on information available to the Company
as of the date hereof, and the Company assumes no obligation to
update any forward-looking statements. You are advised, however,
to consult any future disclosures we make on related subjects in
future filings with the Securities and Exchange Commission
(SEC). Forward-looking statements involve known and
unknown risks, uncertainties and other factors which may cause
the actual results to differ materially from any future results,
performance or achievements expressed or implied by such
forward-looking statements. Such factors may include, among
others, those factors set forth under the heading Risk
Factors beginning in Part I, Item 1A on this
Form 10-K.
PART I
|
|
(a)
|
General
Development of Business
|
Introduction
Synovis Life Technologies, Inc., a diversified medical device
company, develops, manufactures and markets biological and
mechanical products used by several surgical specialties to
facilitate the repair and reconstruction of soft tissue damaged
or destroyed by disease or injury. Our products include
implantable biomaterials for soft tissue repair, devices for
microsurgery and surgical tools all designed to
reduce risks
and/or
facilitate critical surgeries, improve patient outcomes and
reduce healthcare costs.
History
Synovis Life Technologies, Inc. was incorporated in July of
1985. In 1985, the Company was spun-off to the shareholders of
its then parent company, thereafter operating as a separate
public company.
In 2001, we acquired Micro Companies Alliance, Inc.
(MCA), a Birmingham, Alabama company that provides
products to the microsurgery market. MCAs products
include, among others, the Microvascular Anastomotic Coupler, a
patented technology for connecting small veins and arteries
faster, easier and as effectively as conventional suturing.
MCAs name has since been changed to Synovis Micro
Companies Alliance, Inc.
During fiscal 2006 and fiscal 2007, we transitioned from a
third-party distribution sales force to a direct sales force in
the U.S.
In January 2008, we sold substantially all of the assets of our
former interventional business to Heraeus Vadnais, Inc. and its
related entities. Our interventional business developed and
manufactured metal and polymer components and assemblies used in
or with implantable or minimally invasive devices for cardiac
rhythm management, neurostimulation, vascular and other
procedures. Operating results pertaining to our
1
former interventional business for the fiscal year ended
October 31, 2008 has been reclassified and presented as
discontinued operations. Unless otherwise indicated, the
following description of our business refers only to our
continuing operations.
On July 17, 2009, the Company, through its wholly-owned
subsidiary Synovis Orthopedic and Woundcare, Inc.
(Ortho & Wound), completed the acquisition
of substantially all of the assets of Pegasus Biologics, Inc., a
Delaware corporation. Our Ortho & Wound business is
focused on developing advanced biological solutions for soft
tissue repair, primarily within the orthopedic and wound care
markets.
Our principal executive offices are located at 2575 University
Avenue W., St. Paul, Minnesota
55114-1024.
We can be contacted by telephone at
(651) 796-7300,
by facsimile at
(651) 642-9018,
or by electronic mail at info@synovislife.com. Our website is
www.synovislife.com. We make available free of charge on
our website our annual reports on
Form 10-K,
quarterly reports on
Form 10-Q,
current reports on
Form 8-K,
and amendments to those reports filed or furnished pursuant to
Section 13(a) or 15(d) of the Securities Exchange Act of
1934 as soon as reasonably practicable after filing such
material with, or furnishing it to, the SEC.
|
|
(b)
|
Financial
Information about Industry Segments
|
We operate as three segments but these segments have similar
economic characteristics and are similar in the nature of
products sold, types of customers, methods used to sell our
products and regulatory environment. Accordingly, management
believes that we meet the criteria for aggregating our operating
segments of our operations into a singular reporting segment.
|
|
(c)
|
Narrative
Description of Business
|
The table below summarizes the revenue contributed by our
significant products or product lines for the periods indicated.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended October 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
|
$
|
|
|
%
|
|
|
$
|
|
|
%
|
|
|
$
|
|
|
%
|
|
|
|
($ in thousands)
|
|
|
Net Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Veritas®
|
|
$
|
14,368
|
|
|
|
21
|
%
|
|
$
|
8,757
|
|
|
|
15
|
%
|
|
$
|
4,468
|
|
|
|
9
|
%
|
Peri-Strips®
|
|
|
19,414
|
|
|
|
28
|
%
|
|
|
19,384
|
|
|
|
33
|
%
|
|
|
17,653
|
|
|
|
35
|
%
|
Tissue-Guard
|
|
|
16,550
|
|
|
|
24
|
%
|
|
|
15,806
|
|
|
|
27
|
%
|
|
|
14,477
|
|
|
|
29
|
%
|
Microsurgery
|
|
|
11,020
|
|
|
|
16
|
%
|
|
|
8,668
|
|
|
|
15
|
%
|
|
|
7,749
|
|
|
|
16
|
%
|
Surgical Tools and other
|
|
|
5,335
|
|
|
|
8
|
%
|
|
|
5,531
|
|
|
|
10
|
%
|
|
|
5,453
|
|
|
|
11
|
%
|
Orthopedic and Wound
|
|
|
1,878
|
|
|
|
3
|
%
|
|
|
65
|
|
|
|
0
|
%
|
|
|
|
|
|
|
0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Net Revenue
|
|
$
|
68,565
|
|
|
|
100
|
%
|
|
$
|
58,211
|
|
|
|
100
|
%
|
|
$
|
49,800
|
|
|
|
100
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Domestic
|
|
$
|
57,700
|
|
|
|
84
|
%
|
|
$
|
49,290
|
|
|
|
85
|
%
|
|
$
|
42,190
|
|
|
|
85
|
%
|
International
|
|
|
10,865
|
|
|
|
16
|
%
|
|
|
8,921
|
|
|
|
15
|
%
|
|
|
7,610
|
|
|
|
15
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Worldwide
|
|
$
|
68,565
|
|
|
|
100
|
%
|
|
$
|
58,211
|
|
|
|
100
|
%
|
|
$
|
49,800
|
|
|
|
100
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Products,
Markets and Competition
Business
Description
We are a diversified medical device company which develops,
manufactures and markets biological and mechanical products used
by several surgical specialties to facilitate the repair and
reconstruction of soft tissue damaged or destroyed by disease or
injury. Our products include implantable biomaterials for soft
tissue repair, devices for microsurgery and surgical
tools all designed to reduce risks
and/or
facilitate critical surgeries, improve patient outcomes and
reduce healthcare costs.
2
Biomaterial
Products
A core competency of our business is the development and
manufacture of implantable biomaterial products for use by
surgeons in various procedures where reinforcing, reconstructing
and repairing tissue or preventing leaks of air, blood or other
bodily fluids is desirable to achieve a favorable outcome. The
historical choice when tissue repair is necessary has been to
use autologous tissues, requiring the surgeon to excise tissue
from another part of the patients body. Harvesting tissue
from a second surgical site may increase procedure cost, time
and the risk of complications, leading to additional pain and
recovery time for the patient. Use of an available,
off-the-shelf
implantable medical product, whether tissue-based or synthetic,
is an alternative to harvesting autologous tissue from the
patient and is a means to reduce surgical costs and improve
patient outcomes.
Our biomaterial products are produced from bovine and equine
pericardium. Many of our products characteristics and
competitive advantages are derived from the pericardiums
collagen composition. Collagen, a fibrous protein, makes the
pericardium durable and provides performance characteristics
superior to synthetics and similar to autologous tissue.
We process pericardium using proprietary and patented
technologies to create three distinct product platforms:
|
|
|
|
|
Our Veritas tissue processing results in an extremely strong and
conformable biomaterial. Once implanted, Veritas acts as a
scaffold that is rapidly revascularized and repopulated by the
patients surrounding tissue. Animal studies have
demonstrated the formation of new blood vessels (angiogenesis)
and cell in-growth with Veritas as early as 28 days
post-implant. The Veritas tissue format is used to manufacture
our Veritas Collagen Matrix, Peri-Strips Veritas and Peri-Strips
Veritas Circular products.
|
|
|
|
Our Apex tissue processing creates a permanent patch or buttress
that provides enduring strength and reinforcement to a repair
site or staple line. Apex processing is used to manufacture our
Tissue-Guard and Peri-Strips Apex products.
|
|
|
|
Our flexible cross-linking technologies are based on proprietary
stabilization and sterilization processes, resulting in a safe,
sterile, structurally sound, biologic scaffold of highly
organized collagen for soft tissue repair. We have exclusive
worldwide licenses for these processes for use in orthopedic,
oral/dental, spinal and neurological, abdominal and thoracic,
breast and wound applications and such licenses are used to
manufacture our Ortho & Wound
OrthADAPT®
Bioimplant and
Unite®
Biomatrix products.
|
Veritas. Veritas is used in surgery to
repair soft tissue. Veritas accounted for 21% of our revenue in
fiscal 2010, compared with 15% in fiscal 2009. We launched
Veritas into the complex ventral hernia repair market in the
U.S. during fiscal 2007, following our 510(k) market
clearance which indicated Veritas as having minimal tissue
attachment. We launched Veritas into the breast reconstruction
market in the U.S. in fiscal 2008. Veritas has been used by
surgeons in a broad range of procedures since launch, including
breast reconstruction, chest wall repair and repair of complex
ventral, hiatal, and parastomal hernias. Overall surgical
results and experience with Veritas in these applications have
been favorable. In the fourth quarter of fiscal 2009, we
launched Veritas in Europe after obtaining CE Mark approval for
soft tissue repair of breast reconstruction, chest wall repair
and a variety of hernia indications.
Peri-Strips. Peri-Strips
(PSD) is a biomaterial stapling buttress used as
reinforcement at a surgical staple line to reduce the risk of
potentially fatal leaks, most significantly in bariatric
surgery, a treatment for morbid obesity, as well as in certain
thoracic procedures. Peri-Strips accounted for 28% of our
revenue in fiscal 2010, compared to 33% in fiscal 2009.
In bariatric surgery, Peri-Strips are proven to reduce the
incidence of gastric leaks and to reduce bleeding at the staple
line. Because of the clean visual field provided by the improved
hemostasis and the atraumatic tissue manipulation provided by
Peri-Strips, it can also facilitate a quicker and safer surgical
procedure.
Peri-Strips
is typically applied during the formation of the gastric pouch
in a Roux-en-Y gastric bypass procedure. Peri-Strips may also be
applied to other gastric stapling sites such as the J-J
anastomosis of the
3
Roux-en-Y procedure and the gastric sleeve staple line of the
sleeve gastrectomy procedure. Peri-Strips are also utilized in
certain thoracic surgeries (blebectomies, bullectomies, wedge
resections, segmentectomies, and lobectomies) and are proven to
reduce bleeding and air leaks at the staple line during lung
resection procedures.
Tissue-Guard. Our Tissue-Guard family
of products is used to repair and replace damaged tissue in an
array of surgical procedures, including cardiac, vascular,
thoracic, and neurologic procedures. Apex Processing, used to
manufacture Tissue-Guard products, is designed to retain the
intrinsic nature of bovine pericardial collagen with improved
biocompatibility, performance and safety. Tissue-Guard products
accounted for 24% of our revenue in fiscal 2010, compared to 27%
in fiscal 2009. Tissue-Guard products offer exceptional strength
and durability, resistance to leakage, autologous-like handling
characteristics and proven clinical performance. Since their
introduction, Tissue-Guard products have been used in over
950,000 procedures, including use for pericardial closure,
intracardiac defect repair, peripheral vascular repair and
reconstruction, dural closure and soft tissue repairs.
Ortho & Wound. Our
Ortho & Wound products include the OrthADAPT
Bioimplant and Unite Biomatrix products. OrthADAPT Bioimplant
received FDA marketing clearance in fiscal 2005 and is used in
numerous orthopedic applications, including rotator cuff and
Achilles tendon repair, where there is a clinical need to
reinforce the repair. Unite Biomatrix received FDA marketing
clearance in fiscal 2006 and offers treatment for chronic
wounds, such as diabetic foot ulcers and pressure ulcers. Unite
Biomatrix provides a durable, collagen structure that can be
applied to the wound easily and maintains its integrity while
promoting wound healing.
Microsurgery
In addition to our biomaterial products, our business offers
medical devices for microsurgery. The primary device within this
product group is the Microvascular Anastomotic Coupler (the
Coupler), a mechanical anastomotic product comprised
of a pair of implantable, single-use rings. The Coupler is
available in seven sizes, ranging from 1.0mm to 4.0mm in
diameter, in half millimeter increments. The Coupler enables
microsurgeons in numerous surgical specialties, including
plastic and reconstructive, head and neck, orthopedic and hand,
to perform highly effective anastomotic microsurgical procedures
(the connecting of small veins or arteries) faster, easier and
as or more dependably than traditional suture or sleeve
anastomosis.
In the third quarter of fiscal 2010, we initiated our full
U.S. market launch of the Flow
Coupler®.
The Flow Coupler enhances our Microsurgery product offerings by
combining our existing Coupler with Doppler technology, enabling
physicians to verify and monitor blood flow.
In addition to the Coupler, we sell several other products to
the microsurgery market. These include the GEM Microclip, a
hemostatic clip designed to securely ligate vessels and provide
for atraumatic occlusion, as well as the Neurotube, a device
designed to assist in the reconnection of severed nerves. We
also distribute product lines for other companies in the
microsurgery market, including the S&T microsurgery
instrument product line.
Competition
Our products compete primarily on the basis of product
performance, quality and service. The surgical markets in which
we compete worldwide are characterized by intense competition.
These markets are typically dominated by very large, established
manufacturers that have broader product lines, greater
distribution capabilities, substantially greater capital
resources and larger marketing, research and development staffs
and facilities. Many of these competitors offer broader product
lines within our specific product market, particularly in our
surgical tool markets
and/or in
the general field of medical devices and supplies. Broad product
lines give many of our competitors the ability to negotiate
exclusive, long-term medical device supply contracts and,
consequently, the ability to offer comprehensive pricing for
their products, including those that compete with our products.
By offering a broader product line in the general field of
medical devices and supplies, competitors may also have an
advantage in marketing competing products to group purchasing
organizations, health maintenance organizations and other
managed care organizations that increasingly seek to reduce
costs by centralizing and consolidating their purchasing
functions.
4
Competition for our biomaterial products is primarily from
products comprised of synthetic materials, other xenograft
tissues and human cadaveric tissue. The ability of these
products to compete with our biomaterial products varies based
on each such products indications for use, relative
features and benefits and surgeon preference. We believe that
the collagen characteristics exclusive to pericardial tissue,
the strength of the multi-directional fibers of the pericardial
substrate, the proprietary tissue-treatment process and the
purification process we employ offer significant benefits in
product performance over competitive cadaveric tissue and
synthetic materials.
Currently, we believe the major competitors to Veritas include
KCI Corporation, Covidien, Ltd., Ethicon, Inc., C.R. Bard, Inc.,
and Cook Group, Inc. We believe the major competitors to our
Tissue-Guard products include Cook Group, Inc., Integra
Lifesciences Corporation, and Getinge AB. We believe the major
competitors to our Ortho & Wound products include
Wright Medical Group, Inc., Integra Lifesciences Corporation,
Advanced BioHealing, Inc. and Organogenesis.
At the beginning of fiscal 2009, there were two primary
companies, W.L. Gore & Associates, Inc. and
Cook Group, Inc., which offered buttress products that
competed with Peri-Strips. In the second quarter of fiscal 2009,
Covidien Ltd., one of the two primary companies which offer
surgical staplers on which our
Peri-Strips
products are used, launched a buttress product supplied integral
with their stapler cartridges. We are addressing the Covidien
competitive threat by highlighting the clinical history of
Peri-Strips through our expanded direct sales force, the
development of product enhancements and strengthened efforts to
convert additional non-buttressing surgeons.
Peri-Strips also face indirect forms of competition, which
include alternate surgical techniques such as oversewing the
staple line and alternative bariatric procedures which do not
use surgical staplers or buttresses such as gastric banding.
Synthetic materials may be less expensive to produce and to the
extent that comparable synthetic materials are available and
effective in surgical procedures, we face significant price
competition for our biomaterial products. There are other
multi-purpose patches made from bovine and other types of animal
tissue that compete with our products. Cadaveric tissue from
tissue banks or from commercial distributors is utilized in
breast reconstruction, hernia repair, neurological surgery and
urologic procedures. There can be no assurance that competing
products or indirect forms of competition will not achieve
greater acceptance or that future products or alternative
treatments for morbid obesity will not offer similar or enhanced
performance advantages.
Within our microsurgical products, our Coupler faces indirect
forms of competition, primarily hand suturing as an alternative
surgical technique. Competition to our Flow Coupler includes
blood flow monitoring products from Cook Group and ViOptix Inc.
Intellectual
Property
We believe that in order to maintain a competitive advantage in
the marketplace, we must develop and maintain protection of the
proprietary aspects of our technology. We rely on a combination
of patent, trademark, confidentiality, trade secret and other
intellectual property rights and measures to aggressively
protect intellectual property we deem important to our business.
We have developed a patent portfolio internally, as well as
through acquisitions, that cover many aspects of our product
offerings. As of October 31, 2010, we owned or licensed
approximately 98 U.S. and foreign patents and 54
U.S. and foreign pending patent applications. The
expiration dates of our material patents range from fiscal 2014
to fiscal 2024.
Synovis holds key patents related to Veritas Collagen Matrix in
both wet and dry forms, patents related to the Peri-Strip Dry in
both linear and circular formats, as well as the microanastomic
Coupler and Flow Coupler. Synovis has exclusive rights to
technology used in the cross-linking and sterilization of our
Ortho & Wound products.
We own trademarks on
Synovis®
as well as trade names used in conjunction with the sale of most
of our products, including Peri-Strips and Veritas.
5
We manufacture, market and sell our products both under our own
patents as well as license agreements. While we believe that our
patents are valuable, our knowledge and experience, our product
development teams and marketing staff, and our confidential
information regarding our manufacturing processes, materials and
product design have been equally important in providing for and
maintaining our proprietary product offering. To protect this
value, we have established policies and procedures, as well as
requiring as a condition of employment, all employees to execute
a confidentiality agreement with respect to proprietary
information and the assignment of intellectual property to us.
We also rely on unpatented proprietary technology and know-how.
We seek to protect our trade secrets and proprietary know-how
with confidentiality agreements with our employees, consultants
and vendors.
There has been substantial litigation regarding patent and other
intellectual property rights in the medical device industry. We
have strongly defended, and will continue to defend, our
intellectual property. Despite our measures to protect our
intellectual property, however, we cannot be certain that the
measures we take to protect our intellectual property will be
successful. These risks are discussed in more detail in this
Report in Part I, Item 1A, Risk Factors under the
heading We may not be able to adequately enforce or
protect our intellectual property rights or to protect ourselves
against the infringement claims of others.
Marketing
and Customers
Our marketing and sales strategies include supporting our
superior quality products with sales and marketing programs.
These programs include advertising and direct mail campaigns,
participation in trade shows, support of key surgeons
gatherings, publication and presentation of clinical data and
new product information, and collaboration with key surgeons on
educational activities and internet-based programs. An important
strategy of our marketing programs is to identify and assess
customer needs. This is accomplished by developing and
maintaining a close working relationship with the hospitals and
surgeons who purchase and use our products and through
observations and interactions with our customers.
In the U.S., we utilize a direct sales model for all products
except for our Ortho & Wound products. As of
October 31, 2010, we have 56 direct sales representatives
selling our Peri-Strips, Veritas, Tissue-Guard and Surgical
tools and other products. Additionally, we have 9 direct sales
representatives selling our microsurgery products.
Internationally, we utilize an independent distributor sales
network to sell these products.
For our Ortho and Wound products, we utilize a hybrid sales
model in the U.S. comprised of both direct sales
representatives and independent representative groups. As of
October 31, 2010, we have eight direct sales
representatives and 15 independent representative groups (each
with multiple sales representatives) in the U.S. This
structure presently provides sales coverage to approximately
three-quarters of the U.S. population. We expect to appoint
additional independent distributors in the future to complete
our coverage in the U.S. Internationally, we have three
independent distributors serving Italy, Spain and Germany, and
are presently seeking to expand our European coverage through
the appointment of additional independent distributors.
Additional
Information Regarding Our Business
Backlog
Based on our experience, we believe that backlog is not a
meaningful predictor of future revenue levels of our business.
Raw
Materials
We acquire bovine pericardium for use in our biomaterial
products from United States Department of Agriculture
(USDA) inspected abattoirs as well as a USDA
approved source in New Zealand. We acquire equine pericardium
for use in our biomaterial products from USDA approved abattoirs
located in Mexico and Canada. The supply of bovine and equine
pericardium, as well as other raw materials, is currently
adequate. We have not experienced any product shortages arising
from interruptions in the supply of any raw materials or
components, and have identified alternative sources of supply
for significant raw materials and components,
6
although at times certain materials may be single
sourced due either to the complex nature or minimal
requirements of various components we purchase.
Research
and Development
As a component of our business strategy, we continue to make a
significant investment in research and development
(R&D) as well as new product design and
engineering. R&D expense for fiscal 2010, 2009 and 2008 was
$4,393,000, $3,798,000 and $3,248,000, respectively.
The R&D activities we expect to advance in fiscal 2011
include expanding the size offerings and indications for use of
our Veritas product into new markets, providing research and
clinical data to support the use of Veritas in various surgical
procedures, exploring other process improvements and product
enhancements for our proprietary biomaterial products, advancing
the size offerings and technology of the Flow Coupler and
providing research and clinical data to support the launch of
the ProCuff product, an arthroscopically delivered augmentation
device for rotator cuff repair.
Governmental
Regulation
General
Our business operates in a medical device marketplace subject to
extensive and rigorous regulation by the Food and Drug
Administration (FDA) and by comparable agencies in
foreign countries. In the United States, the FDA regulates the
design control, development, manufacturing, labeling, record
keeping and surveillance procedures for medical devices.
Food
and Drug Administration
FDA regulations classify medical devices based on perceived risk
to public health as either Class I, II or III
devices. Class I devices are subject to general controls,
Class II devices are subject to special controls and
Class III devices are subject to pre-market approval
(PMA) requirements. While most Class I devices
are exempt from pre-market submission, it is necessary for most
Class II devices to be cleared by a 510(k) pre-market
notification prior to marketing. 510(k) establishes that the
device is substantially equivalent to a device that
was legally marketed prior to May 28, 1976, the date on
which the Medical Device Amendments of 1976 became effective.
The 510(k) pre-market notification must be supported by data
establishing the claim of substantial equivalence to the
satisfaction of the FDA. The process of obtaining a 510(k)
clearance typically can take several months to a year or longer.
If the product is notably new or different and substantial
equivalence cannot be established, the FDA will require the
manufacturer to submit a PMA application for a Class III
device that must be reviewed and approved by the FDA prior to
sale and marketing of the device in the United States. The
process of obtaining PMA approval can be expensive, uncertain,
lengthy and frequently requires anywhere from one to several
years from the date of FDA submission, if approval is obtained
at all. The FDA controls the indicated uses for which a product
may be marketed and strictly prohibits the marketing of medical
devices for unapproved uses. The FDA can withdraw products from
the market for failure to comply with laws or the occurrence of
safety risks.
Our microsurgery instruments and the Lap Assist Fascia Closure
System are Class I medical devices. The rest of our
products are classified as Class II medical devices and
have received 510(k) marketing clearance from the FDA. Our
manufacturing operations are subject to periodic inspections by
the FDA, whose primary purpose is to audit the Companys
compliance with the Quality System Regulations published by the
FDA and other applicable government standards. Strict regulatory
action may be initiated in response to audit deficiencies or to
product performance problems. We believe that our manufacturing
and quality control procedures are in compliance with the
requirements of the FDA regulations.
Recent concerns have been raised by the public, internal FDA
staffers and Congress whether the current FDA 510(k) program
achieves its goals of making safe and effective devices
available to the public while also fostering innovation. In
August 2010, the FDA Center for Devices and Radiological Health
(CDRH) released two major FDA reports recommending
changes to be taken by CDRH. The first report provides
recommendations on how to strengthen the 510(k) program and the
second on how to incorporate new scientific
7
information into regulatory decision making. The recommendations
are preliminary and the FDA is presently soliciting public input
on these recommendations. If recommendations are adopted from
these evaluations, any newly developed products or new
indications for use for our existing products may be subjected
to a more rigorous premarket review process. In addition, the
FDA has requested the Institute of Medicine conduct an
independent study of the 510(k) program on whether legislative,
regulatory or administrative changes are needed. A final report
is expected in the summer of 2011.
International
Regulation
International regulatory bodies have established varying
regulations governing product standards, packaging and labeling
requirements, import restrictions, tariff regulations, duties
and tax. Many of these regulations are similar to those of the
FDA. With the exception of the European Union (EU),
Canada and Australia, we typically rely on our independent
distributors covering a given country to comply with the foreign
regulatory requirements, including registration of our devices
with the appropriate governmental authorities. We believe we are
in compliance with the regulatory requirements in the foreign
countries in which our medical devices are marketed. We do,
however, face certain regulatory risks in international markets
related to our bovine tissue products, which are discussed in
Part I, Item 1A of this report.
The registration system in the EU for our medical devices
requires that our quality system conform to international
quality standards and that our medical devices conform to
essential requirements set forth by the Medical
Device Directive (MDD). Manufacturing facilities and
processes under which our Ortho & Wound medical
devices are produced are inspected and audited by the National
Standards Authority of Ireland (NSAI). Manufacturing
facilities and processes under which all of our other medical
devices are produced are inspected and audited by the British
Standards Institute (BSI). These audits verify our
compliance with the essential requirements of the MDD, as well
as supplementary requirements for medical devices
incorporating animal tissue. These certifying bodies
verify that our quality system conforms to the international
quality standard ISO 13485:2003 and that our products conform to
the essential requirements and supplementary
requirements set forth by the MDD for the class of medical
devices we produce. These certifying bodies also certify our
conformity with both the quality standards and the MDD
requirements, entitling us to place the CE mark on
all of our current medical devices.
Third
Party Reimbursement
The availability and level of reimbursement from third-party
payers for procedures utilizing our products is significant to
our business. Our products are purchased primarily by hospitals
and other end-users, who in turn bill various third party payers
for the services provided to the patients. These payers, which
include Medicare, Medicaid, private health insurance plans and
managed care organizations, reimburse all or part of the costs
and fees associated with the procedures utilizing our products.
In response to the focus of national attention on rising health
care costs, a number of changes to reduce costs have been
proposed or have begun to emerge. There have been, and may
continue to be, proposals by legislators, regulators and third
party payers to curb these costs. The development or increased
use of more cost effective treatments for diseases could cause
such payers to decrease or deny reimbursement for surgeries or
devices to favor alternatives that do not utilize our products.
A significant number of Americans enroll in some form of managed
care plan. Higher managed care utilization typically drives down
the payments for health care procedures, which in turn places
pressure on medical supply prices. This causes hospitals to
implement tighter vendor selection and certification processes,
by reducing the number of vendors used, purchasing more products
from fewer vendors and trading discounts on price for guaranteed
higher volumes to vendors. Hospitals have also sought to control
and reduce costs over the last decade by joining group
purchasing organizations or purchasing alliances. We cannot
predict what continuing or future impact these practices, the
existing or proposed legislation, or such third-party payer
measures within a constantly changing healthcare landscape may
have on our future business, financial condition or results of
operations.
8
Employees
On October 31, 2010, we employed approximately
310 full-time and part-time individuals. Our employees are
not represented by a union, and we consider our relationship
with our employees to be good.
|
|
(d)
|
Financial
Information About Geographic Areas
|
For information regarding net revenue by geographic area, please
refer to Note 5 to our consolidated financial statements
under Item 8 of this report.
The following factors are important and should be considered
carefully in connection with any evaluation of our business,
financial condition, results of operations, prospects and an
investment in our common stock. Additionally, the following
factors could cause our actual results to materially differ from
those reflected in any forward-looking statements.
We may
not be able to sustain or manage our growth.
We have achieved notable revenue growth over the past several
years. Our business has increased revenue 18% in fiscal 2010,
17% in fiscal 2009 and 32% in fiscal 2008. There can be no
assurance that we can manage the significant challenges that
accompany such growth, including management of an increasingly
diverse product portfolio and provision of necessary
infrastructure. In addition, there can be no assurance that we
will be able to identify and successfully consummate and
integrate acquisitions or develop new products to sustain rates
of revenue growth and profitability in future periods comparable
to those experienced over the past several years.
Sales
growth of our Ortho and Wound products in the marketplace is
uncertain and we expect to incur significant operating losses
from this business unit in the future.
While we achieved revenues of $1,878,000 from our Ortho and
Wound products during fiscal 2010, we incurred an operating loss
of $5,850,000 in this business unit during the year. We plan to
invest significantly in this business unit in the future to
drive revenue growth, and we expect to incur significant
operating losses until a return on these investments is
achieved. There can be no assurance, however, that our
investments will result in our desired sales levels or that our
Ortho and Wound business unit will be able to achieve such
break-even operating performance. If long-term profitable
operating results are not achieved, we may be required to record
an impairment of Ortho and Wounds identifiable intangible
assets that could be material to our results of operations.
We face
significant competition from established competitors in the
medical device industry.
We face intense competition. The medical device industry is
highly competitive and characterized by rapid innovation and
technological change. We expect technology to continue to
develop rapidly, and our success will depend to a large extent
on our ability to maintain a competitive position with our
technology. There can be no assurance that we will be able to
compete effectively in the marketplace or that products
developed by our competitors will not render our products
obsolete or non-competitive. Similarly, there can be no
assurance that our competitors will not succeed in developing or
marketing products that are viewed by surgeons as providing
superior clinical performance
and/or are
less expensive relative to the products we currently market or
may develop.
Established companies manufacture and sell products that compete
with each of our products or capabilities. Some of the companies
with whom we compete have greater sales
and/or
distribution capabilities, substantially greater capital
resources, larger marketing, research and development staffs and
larger facilities. In addition, many of our competitors offer
broader product lines within our specific product markets. Broad
product lines may give our competitors the ability to negotiate
exclusive, long-term medical product supply contracts and the
ability to offer comprehensive pricing for their products. There
can be no assurance that we will be able to compete effectively
with such manufacturers.
9
We continue to evaluate new market opportunities for our
existing products. This process involves numerous steps,
including, but not limited to, identifying meaningful new
markets for our products, performing in-depth research and
analysis to forecast the market potential for our products in
these new markets, obtaining the required regulatory market
clearances, developing an attractive value proposition for
potential customers, and translating this value proposition into
meaningful revenue. Due to the inherent complexity of this
process, there can be no assurance that we will be able to
effectively enter new markets with our existing or newly
developed products.
We may
not be able to adequately enforce or protect our intellectual
property rights or to protect ourselves against the infringement
claims of others.
We protect our technology through patents, trade secrets, and
proprietary know-how. We also seek to protect our technology
through confidentiality agreements with employees, consultants
and other parties.
There can be no assurance that our trade secrets or
confidentiality agreements will adequately protect our
proprietary information or, in the event of a breach of any
confidentiality agreement, that we will have adequate remedies.
Additionally, there can be no assurance that any pending or
future patent applications will result in issued patents, or
that any current or future patent, regardless of whether we are
an owner or licensee of such patent, will not be challenged,
invalidated or circumvented or that the rights granted
thereunder or under our licensing agreements will provide a
competitive advantage to us. Furthermore, there can be no
assurance that others will not independently develop similar
technologies or duplicate any technology developed by us, or
that our technology does not or will not infringe patents or
other rights owned by others.
The medical device industry is characterized by frequent and
substantial intellectual property litigation, and competitors
may resort to intellectual property litigation as a means of
competition. Intellectual property litigation is complex and
expensive, and the outcome of such litigation is difficult to
predict.
From time to time, we may become involved in litigation which is
ordinary, routine litigation incidental to its business.
Further, product liability claims may be asserted in the future
relative to events not known to management at the present time.
Management believes that our risk management practices,
including our insurance coverage, are reasonably adequate to
protect against potential material liability losses.
Oversight
of the medical device industry might affect the manner in which
we may sell medical devices.
There are laws and regulations that govern the means by which
companies in the healthcare industry may market their products
to healthcare professionals and may compete by discounting the
prices of their products, including for example, the federal
Anti-Kickback Statute, the federal False Claims Act, the federal
Health Insurance Portability and Accountability Act of 1996, and
state law equivalents to these federal laws that are meant to
protect against fraud and abuse. Violations of these laws are
punishable by criminal and civil sanctions, including, but not
limited to, in some instances civil and criminal penalties,
damages, fines, and exclusion from participation in federal and
state healthcare programs, including Medicare and Medicaid.
Although we exercise care in structuring our sales and marketing
practices and customer discount arrangements to comply with
those laws and regulations, we cannot assure you that:
|
|
|
|
|
government officials charged with responsibility for enforcing
those laws will not assert that our sales and marketing
practices or customer discount arrangements are in violation of
those laws or regulations; or
|
|
|
|
government regulators or courts will interpret those laws or
regulations in a manner consistent with our interpretation.
|
ADVAMED, the principal U.S. trade association for the
medical device industry, has put in place a model code of
conduct that sets forth standards by which its members
should abide in the promotion of their products. We have
policies and procedures in place for compliance that we believe
are consistent with those set forth in the ADVAMED Code, and we
provide routine training to our sales and marketing personnel on
our policies regarding sales and marketing practices.
Nevertheless, the sales and marketing practices of our industry
have been the subject of increased scrutiny from federal and
state government agencies, and we believe that this trend will
continue. For example, recent federal and state legislation
require detailed
10
disclosure of gifts and other remuneration made to health care
professionals. In addition, prosecutorial scrutiny and
governmental oversight, on the state and federal levels, over
some major device companies regarding the retention of
healthcare professionals as consultants has limited the manner
in which medical device companies may retain healthcare
professionals as consultants. We have in place policies to
govern how we may retain healthcare professionals as consultants
that reflect the current climate on this issue and provide
training on these policies. Finally, various hospital
organizations, medical societies and trade associations are
establishing their own practices that may require detailed
disclosures of relationships between healthcare professionals
and medical device companies or ban or restrict certain
marketing and sales practices such as gifts and business meals.
Quality
issues with our processes, goods and services could harm our
reputation for producing high quality products and erode our
competitive advantage.
Quality is extremely important to us and our customers due to
the serious and costly consequences of product failure. Our
quality certifications are critical to the marketing success of
our products. If our products fail to meet these standards or
fail to adapt to evolving standards, our reputation as a
manufacturer of high quality products could be harmed, our
competitive advantage could be damaged, we could lose customers
and market share, and our revenues and results of operations
could decline.
Our
failure to obtain regulatory clearance/approval and maintain
regulatory compliance for any of our products would impact our
ability to generate revenue from those products.
We must comply with FDA regulations to market our products in
the United States. The medical device industry in
which our business operates is subject to extensive and rigorous
regulation by the FDA and by comparable agencies in foreign
countries. In the United States, the FDA regulates the design
control, development, manufacturing, labeling, record keeping
and surveillance procedures for our medical devices.
The process of obtaining marketing clearance or approvals from
the FDA for new products and new applications for existing
products can be time-consuming and expensive, and there is no
assurance that such clearance/approvals will be granted, or that
the FDA review will not involve delays that would adversely
affect our ability to commercialize additional products or
additional applications for existing products. Some of our
products that are in the research and development stage may be
subject to a lengthy and expensive pre-market approval process
with the FDA. The FDA has the authority to control the indicated
uses of a medical device. Products can also be withdrawn from
the market due to failure to comply with regulatory standards or
the occurrence of unforeseen problems. The FDA regulations
depend heavily on administrative interpretation, and there can
be no assurance that future interpretations made by the FDA or
other regulatory bodies, with possible retroactive effect, will
not adversely affect us.
Our facilities and processes are subject to
regulation. The FDA, various state agencies and
foreign regulatory agencies inspect our facilities to determine
whether we are in compliance with various regulations relating
to quality systems, such as manufacturing practices, validation,
testing, quality control, product labeling and product
surveillance. A determination that we are in violation of such
regulations could lead to imposition of civil penalties,
including fines, product recalls or product seizures and, in
extreme cases, criminal sanctions, depending on the nature of
the violation.
We must obtain regulatory approvals to market our products
internationally. The registration scheme in the
majority of international markets (e.g. Europe, Canada) for our
products requires that our quality system conforms to
international quality standards. We must remain compliant with
these requirements as well as product standards in order to sell
our products in these countries. There can be no assurance that
we will be able to maintain compliance with these regulations.
In addition, there can be no assurance that we will be
successful in obtaining registration for new product
introductions.
Further, international regulatory bodies have established
varying additional regulations governing product standards,
packaging requirements, labeling requirements, import
restrictions, tariff regulations, duties and tax requirements.
We rely, in part, on our independent distributors to comply with
such foreign regulatory requirements. As a result, our
communication with foreign regulatory agencies may be indirect
as it occurs through the foreign distributor. The inability or
failure of independent distributors to comply with the varying
11
regulations or the imposition of new regulations could restrict
such distributors ability to sell our medical products
internationally and thereby adversely affect our business,
financial condition and results of operations.
Because
many of our biomaterial products are manufactured from bovine
pericardium, perceptions about Bovine Spongiform Encephalopathy
may impact our sales.
Under the direction of the United States Department of
Agriculture (USDA), the U.S. government has had
an active program of surveillance and import controls since the
late 1980s designed to prevent the introduction of Bovine
Spongiform Encephalopathy (BSE) into
U.S. cattle. The USDA program includes certain feed
restrictions which began in 1997. The World Health Organization
has categorized the levels of BSE infectivity of tissue. This
characterization places pericardium (which primarily consists of
collagen) as having no detectable infectivity, the lowest risk
category. The European authorities have specifically reviewed
our biomaterial sourcing and manufacturing processes and have
also certified our bovine pericardium products.
We obtain our raw bovine pericardium for our biomaterial
products from USDA-inspected abattoirs as well as from a USDA
approved source in New Zealand. The bovine pericardium is
collected under strict conditions; inspectors examine each heart
for disease and anomalies prior to harvesting the pericardium.
Additional measures are also taken to ensure brain and spinal
cord matter does not come into contact with the bovine
pericardium. Our bovine-based tissue products are manufactured
with sodium hydroxide, a processing technique recommended by
international experts to remove or inactivate the prion, the
agent believed to cause BSE, should it exist in the tissue. The
bovine pericardium used in our products is sourced from animals
who are 30 months or younger. Sourcing from these younger
animals markedly decreases the likelihood of BSE transmission.
Notwithstanding these safeguards, if the perception of risk
associated with BSE increases, it could have a material adverse
effect on our business, financial condition and results of
operations.
In 2004, the EU enacted medical device regulations that require
product specific evaluation of bovine-based products for
potential BSE patient health risks. All bovine-based medical
products currently sold in the EU are subject to this
evaluation. Our bovine-based products have been evaluated and
have obtained approval, although our Dura-Guard product has not
been approved for sale in France. Currently, none of our
bovine-based products are approved for sale in Japan or Taiwan.
In August 2006, the government of China began prohibiting the
sale of U.S. bovine-based products. We understand that
regulatory approvals will not be granted in the present
environment within those countries for products derived from
bovine pericardium, unless we source bovine pericardium from
countries which they consider at no risk for BSE (e.g. New
Zealand and Australia). Total international sales of our
bovine-based products accounted for 11.3% and 11.5% of our
consolidated net sales for the fiscal years ended
October 31, 2010 and 2009, respectively, and increased 15%
in fiscal 2010. Any prohibition by certain other countries of
U.S. bovine pericardium products as a result of concerns
related to BSE could have an adverse effect on our ability to
maintain or grow international sales of these products.
We may
face the risk of product liability claims and product recalls
that could result in costly and time consuming litigation and
significant liability.
The medical device industry historically has been litigious, and
the manufacture and sale of our products entails an inherent
risk of product liability claims. In particular, our principal
medical devices are designed to be permanently placed in the
human body, and production or other errors could result in an
unsafe product and injury to the patient. Although we maintain
product liability insurance in amounts believed to be adequate,
based upon the nature and risks of our business in general and
our actual experience to date, there can be no assurance that
one or more liability claims will not exceed the coverage limits
of such policies or that such insurance will continue to be
available on commercially reasonable terms, if at all.
Furthermore, we do not have nor do we expect to obtain insurance
covering our costs and losses as the result of any recall of our
products due to alleged defects, whether such a recall is
instituted by us or required by a regulatory agency. A product
liability claim, recall or other claim with respect to uninsured
liabilities or in excess of our insured liabilities could have a
material adverse effect on our business, financial condition and
results of operations.
12
Due to
the unpredictability of the health care industry, our customers
may not be able to receive
third-party
reimbursement for the medical procedures utilizing our
products.
Our products are purchased primarily by hospitals and other
end-users. Hospitals and end-users of our products bill various
third-party payers, including government health programs,
private health insurance plans, managed care organizations and
other similar programs, for the health care goods and services
provided to their patients. Third-party payers may deny
reimbursement if they determine that a procedure was not in
accordance with established third-party payer protocol regarding
treatment methods. Our products are covered by procedure costs
as a component of the overall medical procedure reimbursement
obtained from the third-party payer.
Third-party payers are also increasingly challenging the prices
charged for medical products and services and, in some
instances, have put pressure on medical device suppliers to
lower their prices. While we believe our pricing is appropriate
for the niche markets and technology of our products, we are
unable to predict what changes will occur in the reimbursement
methods used by third-party payers. There can be no assurance
that medical procedures in which our products are used will
continue to be considered cost-effective by third-party payers,
that reimbursement for such procedures will be available or, if
available, will continue, or that third-party payers
reimbursement levels will not adversely affect our ability to
sell our products on a profitable basis. The cost of health care
has risen significantly over the past decade, and there have
been and may continue to be proposals by legislators, regulators
and third-party payers to curb these costs.
Failure by hospitals and other users of our products to obtain
reimbursement from third-party payers for procedures in which
our products are used, changes in third-party payers
policies towards reimbursement for procedures using our products
or legislative action could have a material adverse effect on
our business, financial condition and results of operations.
Our
business, financial condition, results of operations and cash
flows could be significantly and adversely affected by the
recently adopted legislation reforming the United States
healthcare system and if other administration and legislative
proposals are enacted into law.
On March 30, 2010, the Health Care and Education
Reconciliation Act of 2010 (the Reconciliation Bill)
was signed into law by President Obama. The Reconciliation Bill
amended the Patient Protection and Affordable Care Act, which
was signed into law on March 23, 2010. Among other
initiatives, these bills impose a 2.3% excise tax on domestic
sales of medical devices following December 31, 2012. This
enacted excise tax on medical devices could materially and
adversely affect our operating results.
Other elements in the Reconciliation Bill, such as comparative
effectiveness research, an independent payment advisory board
and other provisions could meaningfully change the way
healthcare is developed and delivered, and may materially impact
our business.
Various healthcare reform proposals also have emerged at the
state level. We cannot predict what healthcare initiatives, if
any, will be implemented at the state level or the exact effect
newly enacted laws or any future legislation or regulation will
have on us. However, an expansion in governments role in
the U.S. healthcare industry may lower reimbursements for
our products, reduce medical procedure volumes and adversely
affect our business and results of operations, possibly
materially.
The
current global economic downturn could continue to adversely
impact our business.
A significant portion of our product sales are used in medical
procedures are covered by patient health insurance.
Additionally, a notable percentage of medical procedures
utilizing our products may be considered elective by the
patient. The current global economic downturn may have a
meaningful impact on availability to or affordability of health
insurance, or may impact patient decisions to have an elective
medical procedure performed. This may in turn also impact the
financial condition of our customers. Accordingly, a pronounced
and sustained economic downturn could have a material, adverse
effect on our business, financial condition and results of
operations.
13
We depend
on highly specialized equipment to manufacture our products and
loss of or damage to one of our manufacturing facilities could
result in reduced revenues and significant losses.
We presently have two manufacturing facilities: our Irvine,
California facility which manufactures our Ortho &
Wound products, and our St. Paul, Minnesota facility which
manufactures substantially all of our other products. The loss
of or damage to either of our manufacturing facilities due to
natural disaster, equipment failure or other difficulty could
result in significant delays in production. In the event of such
disaster, re-starting manufacturing activity at our other
location, or locating third-party manufacturers to manufacture
our products in any such event would likely be difficult given
the specialized equipment and processes necessary to produce
those products. Although we maintain business interruption
insurance to mitigate the financial impact on our business, any
sustained period of suspended production would likely have a
material adverse effect on our business, financial condition and
results of operations.
We cannot
predict the outcome of our clinical studies.
In fiscal 2011, we expect to perform several post-clearance
marketing clinical studies for certain of our products, which
are designed to document the comparative strengths of our
products versus competitive products, and also to more fully
understand the role implant techniques and other factors may
affect clinical outcomes. We expect these clinical studies will
require significant investment and may span several years. We
cannot predict the outcome of our clinical studies, nor what
impact, if any, they may have in the marketplace.
Our
strategy to acquire complementary businesses and technologies
involves risk and may result in disruptions to our business by,
among other things, distracting management time and diverting
financial resources.
One of our growth strategies is the acquisition of complementary
businesses and technologies. We may not be able to identify
suitable acquisition candidates, or if we do, we may not be able
to make such acquisitions on commercially acceptable terms. If
we make acquisitions, a significant amount of management time
and financial resources may be required to evaluate or complete
the acquisition and integrate the acquired business into our
existing operations. Even with this investment of management
time and financial resources, an acquisition may not produce the
desired revenue, earnings or business synergies. Acquisitions
involve numerous other potential risks including: assumption of
unanticipated operating problems or legal liabilities, problems
integrating the purchased operations, technologies or products,
diversion of managements attention from our core
businesses, adverse effects on existing business relationships
with suppliers and customers, inaccurate estimates of fair value
made in the accounting for acquisitions and amortization of
acquired intangible assets which would reduce future reported
earnings, and potential loss of customers or key employees of
acquired businesses, among others.
We may
not be able to hire or retain key personnel.
We depend on key management, sales and technical personnel.
Moreover, because of the highly technical nature of our
business, our ability to continue our technological developments
and to market and sell our products depends in large part on our
ability to attract and retain qualified technical, sales and key
management personnel. Competition for qualified personnel is
intense, and we cannot ensure that we will be able to attract
and retain the individuals we need. The loss of key personnel,
or our inability to hire or retain qualified personnel, could
have a materially adverse effect on our business, financial
condition and results of operations.
|
|
Item 1B
|
Unresolved
Staff Comments
|
None.
We have a lease for our corporate headquarters and manufacturing
facility, totaling 65,000 square feet, located at 2575
University Ave. W., St. Paul, Minnesota. The lease expires on
December 31, 2013, and the base rent is currently $724,000
annually.
14
We lease approximately 14,830 square feet for our
Ortho & Wound facility at 4 and 6 Jenner Drive,
Irvine, CA. The lease expires August 31, 2012, and the base
rent is currently $232,000 annually.
We lease approximately 3,750 square feet for our MCA
facility at 439 Industrial Lane, Birmingham, Alabama. The lease
expires June 30, 2011, and the base rent is currently
$37,000 annually.
We pay apportioned real estate taxes and common costs on our St.
Paul, MN and Irvine, CA leased facilities.
|
|
Item 3
|
Legal
Proceedings
|
From time to time, we may become involved in routine litigation
incidental to our business. Further, product liability claims
may be asserted in the future relative to events not known to
management at the present time. Management believes that our
risk management practices, including our insurance coverage, are
reasonably adequate to protect against potential material
product liability losses.
Executive
Officers of the Registrant
Our executive officers, their ages, and the offices they held
and certain biographical information, as of December 1,
2010, are as follows:
|
|
|
|
|
|
|
Name
|
|
Age
|
|
Title
|
|
Richard W. Kramp
|
|
|
65
|
|
|
President and Chief Executive Officer
|
Michael K. Campbell
|
|
|
59
|
|
|
President of Synovis Micro Companies Alliance, Inc.
|
Timothy F. Floeder
|
|
|
52
|
|
|
Vice President of Corporate Development
|
Mary L. Frick
|
|
|
57
|
|
|
Vice President of Regulatory/Clinical/Quality Affairs
|
Daniel L. Mooradian
|
|
|
52
|
|
|
Vice President of Research and Development
|
Brett A. Reynolds
|
|
|
42
|
|
|
Chief Financial Officer, Vice President of Finance and Corporate
Secretary
|
Richard W. Kramp. Mr. Kramp was named
Chief Executive Officer of the Company effective January 2007.
Mr. Kramp has served as President of Synovis Life
Technologies, Inc. since June 2006. From August 2004 to May
2006, he served as President and Chief Operating Officer of the
Companys former interventional business. Prior to joining
the Company, Mr. Kramp most recently served as the
President and Chief Operating Officer of Medical CV, Inc. From
1988 to 2003, Mr. Kramp served as President and Chief
Operating Officer, and then President and Chief Executive
Officer, as well as a Board Member at ATS Medical. From 1978 to
1988, Mr. Kramp held sales and marketing positions at St.
Jude Medical, serving as Vice President of Sales and Marketing
from 1981 to 1988.
Michael K. Campbell. Mr. Campbell has
served as President of Synovis Micro Companies Alliance, Inc.
since the acquisition of MCA by the Company in July 2001. Prior
to the acquisition he was President and CEO of MCA from July
2000 through July 2001. From June 1999 to May 2000,
Mr. Campbell served as Executive Vice President of
PrimeSource Surgical, a specialty medical products distributor.
From 1979 to June 1999, he was a director and Vice President of
Futuretech, Inc., a specialty medical distribution company
serving the southeastern United States.
Timothy F. Floeder. Mr. Floeder has
served as Vice President of Corporate Development of the Company
since May 2008. Prior to joining the Company, Mr. Floeder
served as Vice President of Business Development for Compex
Technologies, Inc. (Compex) from 2003 to 2006, and
upon the sale of Compex to Encore Medical Corporation, served as
interim CEO/managing director of Compexs
U.S. consumer business and Compexs European
subsidiary (Compex S.A.) from 2006 to 2007. In addition,
Mr. Floeder served as a non-employee director for HEI, Inc.
from 2002 to 2007. From 1996 to 2002, Mr. Floeder served as
Managing Director of merger and acquisition services for Miller
Johnson Steichen Kinnard, Inc., advising companies in several
industries, including the medical device industry.
15
Mary L. Frick, M.S.C. Ms. Frick has
served as Vice President of Regulatory/Clinical/Quality Affairs
of the Company since November 2000. She had previously served in
several positions within the Company, including Director of
Regulatory/Clinical/Quality Affairs since November 1998 and as
Group Manager of Regulatory/Clinical/Quality Affairs from June
to November of 1998. From 1984 to June 1998, Ms. Frick held
a series of management positions in Research, Operations and
Regulatory/Clinical Affairs at INCSTAR Corporation, a diagnostic
medical device manufacturer.
Daniel L.
Mooradian, Ph.D. Dr. Mooradian has
served as Vice President of Research and Development since
December 2008. From May 2006 to November 2008,
Dr. Mooradian held various positions at Boston Scientific,
including Director of Preclinical Sciences and Director of the
Research and Technology Center. From January 2005 to April 2006,
Dr. Mooradian served as Vice President of Research and
Development for QuestStar Medical, Inc. From January 2001 to
December 2004, Dr. Mooradian held various positions at
Synovis Life Technologies, Inc., including Director of Research
and Development and Principal Scientist. From September 1987 to
December 2000, Dr. Mooradian held various positions at the
University of Minnesota.
Brett A. Reynolds. Mr. Reynolds has
served as Chief Financial Officer, Vice President of Finance and
Corporate Secretary since April 2005. Prior to April 2005,
Mr. Reynolds served as Director of Finance from September
2003. From October 2001 to September 2003, Mr. Reynolds
served in several financial positions at Chiquita Processed
Foods, LLC, a division of Chiquita Brands International,
ultimately serving as Corporate Controller. From 1991 to 2001,
Mr. Reynolds held a series of audit, accounting and
consulting positions with Deloitte and Touche LLP.
16
PART II
|
|
Item 5
|
Market
for Registrants Common Equity and Related Stockholder
Matters and Issuer Purchases of Equity
Securities
|
Price
Range
Our common stock is currently traded on the Nasdaq Global Market
under the symbol SYNO. The following table sets
forth, for each of the fiscal periods indicated, the range of
high and low closing sale prices per share as reported by the
Nasdaq Global Market.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
2009
|
Fiscal Quarter Ended:
|
|
High
|
|
Low
|
|
High
|
|
Low
|
|
January 31
|
|
$
|
13.30
|
|
|
$
|
11.54
|
|
|
$
|
18.74
|
|
|
$
|
11.62
|
|
April 30
|
|
|
15.78
|
|
|
|
12.47
|
|
|
|
18.10
|
|
|
|
11.60
|
|
July 31
|
|
|
16.28
|
|
|
|
13.61
|
|
|
|
21.45
|
|
|
|
12.90
|
|
October 31
|
|
|
16.26
|
|
|
|
13.80
|
|
|
|
16.05
|
|
|
|
12.06
|
|
Dividends
We have not declared or paid any cash dividends on our common
stock since inception, and our Board of Directors presently
intends to retain all earnings for use in the business for the
foreseeable future.
Shareholders
As of November 30, 2010, there were approximately 5,500
beneficial owners and 900 registered shareholders of our common
stock.
Sales
of Unregistered Securities
None.
Purchases
of Equity Securities
On September 29, 2009, we announced that our Board of
Directors had authorized the repurchase of up to
500,000 shares of its common stock. On March 4, 2010,
the Board of Directors increased the number of shares we are
authorized to repurchase by an incremental 1,000,000 shares
of our common stock, for a total of 1,500,000 shares to be
repurchased. The share repurchases are to be funded using our
existing cash balances and may occur either in the open market
or through private transactions from time to time, in accordance
with SEC regulations. The timing and extent to which we may buy
back shares depends upon market conditions and other corporate
considerations. The repurchase plan does not have an expiration
date.
From inception of the program on September 29, 2009 through
October 31, 2010, we used $7,994,000 to repurchase
606,240 shares at an average price of $13.19 per share. The
following table presents the total number of shares repurchased
from August 1, 2010 through October 31, 2010, the
average price paid per share and the number of shares that were
purchased and the maximum number of shares that may yet be
purchased at October 31, 2010, pursuant to our stock
repurchase program:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Number
|
|
|
Maximum Number
|
|
|
|
|
|
|
|
|
|
of Shares Purchased
|
|
|
of Shares That May
|
|
|
|
Total Number
|
|
|
|
|
|
as Part of Publicly
|
|
|
Yet Be Purchased
|
|
|
|
of Shares
|
|
|
Average Price
|
|
|
Announced Plan or
|
|
|
Under the Plan
|
|
Period
|
|
Purchased
|
|
|
Paid per Share
|
|
|
Program
|
|
|
or Program
|
|
|
August 1, 2010 August 31, 2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,066,219
|
|
September 1, 2010 September 30, 2010
|
|
|
99,559
|
|
|
|
14.61
|
|
|
|
99,559
|
|
|
|
966,660
|
|
October 1, 2010 October 31, 2010
|
|
|
72,900
|
|
|
|
15.02
|
|
|
|
172,459
|
|
|
|
893,760
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
172,459
|
|
|
$
|
14.78
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17
Performance
Graph
In accordance with the rules of the SEC, the following
performance graph compares the performance of our common stock
on the Nasdaq Global Market to the Nasdaq Global Market and to
Nasdaqs Surgical and Medical Instruments and
Supplies Index. The following performance graph compares
the cumulative total shareholder return as of the end of each of
our last five fiscal years on $100 invested at the beginning of
the period and assumes reinvestment of all dividends.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date
|
|
|
|
|
10/31/05
|
|
|
|
10/31/06
|
|
|
|
10/31/07
|
|
|
|
10/31/08
|
|
|
|
10/31/09
|
|
|
|
10/31/10
|
|
Company Index
|
|
|
|
100.0
|
|
|
|
|
81.9
|
|
|
|
|
265.0
|
|
|
|
|
194.1
|
|
|
|
|
133.9
|
|
|
|
|
166.5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nasdaq Market Index
|
|
|
|
100.0
|
|
|
|
|
112.1
|
|
|
|
|
133.3
|
|
|
|
|
82.5
|
|
|
|
|
77.3
|
|
|
|
|
95.7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nasdaq Surgical and Medical Instruments and Supplies Index
|
|
|
|
100.0
|
|
|
|
|
109.7
|
|
|
|
|
151.8
|
|
|
|
|
87.4
|
|
|
|
|
95.7
|
|
|
|
|
107.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18
|
|
Item 6
|
Selected
Financial Data
|
Summary
Statement of Operations Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended October 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
(In thousands except per share data)
|
|
|
Net revenue
|
|
$
|
68,565
|
|
|
$
|
58,211
|
|
|
$
|
49,800
|
|
|
$
|
37,691
|
|
|
$
|
27,743
|
|
Gross margin
|
|
|
49,540
|
|
|
|
41,767
|
|
|
|
34,144
|
|
|
|
24,370
|
|
|
|
16,435
|
|
Operating income (loss)
|
|
|
7,335
|
|
|
|
4,002
|
|
|
|
7,194
|
|
|
|
2,468
|
|
|
|
(3,226
|
)
|
Net income (loss) from continuing operations
|
|
|
4,876
|
|
|
|
2,706
|
|
|
|
6,165
|
|
|
|
3,292
|
|
|
|
(862
|
)
|
Gain on sale of discontinued operations
|
|
|
|
|
|
|
|
|
|
|
5,340
|
|
|
|
|
|
|
|
|
|
Income (loss) from discontinued operations
|
|
|
|
|
|
|
|
|
|
|
(20
|
)
|
|
|
518
|
|
|
|
(619
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
4,876
|
|
|
$
|
2,706
|
|
|
$
|
11,485
|
|
|
$
|
3,810
|
|
|
$
|
(1,481
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings (loss) per share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations
|
|
$
|
0.43
|
|
|
$
|
0.23
|
|
|
$
|
0.50
|
|
|
$
|
0.27
|
|
|
$
|
(0.07
|
)
|
Discontinued operations
|
|
|
0.00
|
|
|
|
0.00
|
|
|
|
0.43
|
|
|
|
0.04
|
|
|
|
(0.05
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
0.43
|
|
|
$
|
0.23
|
|
|
$
|
0.93
|
|
|
$
|
0.31
|
|
|
$
|
(0.12
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings (loss) per share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations
|
|
$
|
0.43
|
|
|
$
|
0.23
|
|
|
$
|
0.48
|
|
|
$
|
0.26
|
|
|
$
|
(0.07
|
)
|
Discontinued operations
|
|
|
0.00
|
|
|
|
0.00
|
|
|
|
0.42
|
|
|
|
0.04
|
|
|
|
(0.05
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
0.43
|
|
|
$
|
0.23
|
|
|
$
|
0.90
|
|
|
$
|
0.30
|
|
|
$
|
(0.12
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
11,262
|
|
|
|
11,588
|
|
|
|
12,395
|
|
|
|
12,225
|
|
|
|
12,004
|
|
Diluted
|
|
|
11,441
|
|
|
|
11,827
|
|
|
|
12,721
|
|
|
|
12,528
|
|
|
|
12,004
|
|
Summary
Balance Sheet Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At October 31,
|
|
|
2010
|
|
2009
|
|
2008
|
|
2007
|
|
2006
|
|
|
(In thousands)
|
|
Working capital
|
|
$
|
66,271
|
|
|
$
|
63,885
|
|
|
$
|
62,097
|
|
|
$
|
66,616
|
|
|
$
|
50,253
|
|
Total assets
|
|
|
97,482
|
|
|
|
93,720
|
|
|
|
97,401
|
|
|
|
94,677
|
|
|
|
80,540
|
|
Shareholders equity
|
|
|
89,467
|
|
|
|
86,011
|
|
|
|
89,861
|
|
|
|
86,953
|
|
|
|
77,049
|
|
|
|
Item 7
|
Managements
Discussion and Analysis of Financial Condition and Results of
Operations
|
The following discussion and analysis of our financial condition
and results of operations should be read together with the
selected consolidated financial data and our financial
statements and the related notes appearing elsewhere in this
report. This discussion and analysis contains forward-looking
statements that involve risks, uncertainties and assumptions.
Our actual results may differ materially from those anticipated
in these forward-looking statements as a result of many factors,
including but not limited to those set forth in Part 1,
Items 1A, Risk Factors, of this report.
Overview
Synovis Life Technologies, Inc., a diversified medical device
company, develops, manufactures and markets biological and
mechanical products used by several surgical specialties to
facilitate the repair and reconstruction of soft tissue damaged
or destroyed by disease or injury. Our products include
implantable biomaterials for soft tissue repair, devices for
microsurgery and surgical tools all designed to
reduce risks
and/or
facilitate critical surgeries, improve patient outcomes and
reduce healthcare costs.
19
Operating
Results Fiscal 2010 ($ in thousands except per share
data)
Net revenue increased 18% during fiscal 2010 to $68,565 from
$58,211 in fiscal 2009. Our operating income was $7,335 in
fiscal 2010, compared to $4,002 in the prior year. Net income
for fiscal 2010 was $4,876, or 43 cents per diluted share,
compared to $2,706, or 23 cents per diluted share during fiscal
2009.
In July 2009, we acquired substantially all of the assets of
Pegasus Biologics, Inc., a company located in Irvine, California
focused on developing advanced biological solutions for soft
tissue repair, primarily within the orthopedic and woundcare
markets. See Note 2 to the consolidated financial
statements included in this report on
Form 10-K
for additional information.
The following table summarizes our net revenue by product group
and geography for fiscal 2010 and fiscal 2009:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
Veritas
|
|
$
|
14,368
|
|
|
|
21
|
%
|
|
$
|
8,757
|
|
|
|
15
|
%
|
Peri-Strips
|
|
|
19,414
|
|
|
|
28
|
%
|
|
|
19,384
|
|
|
|
33
|
%
|
Tissue-Guard
|
|
|
16,550
|
|
|
|
24
|
%
|
|
|
15,806
|
|
|
|
27
|
%
|
Microsurgery
|
|
|
11,020
|
|
|
|
16
|
%
|
|
|
8,668
|
|
|
|
15
|
%
|
Surgical Tools and other
|
|
|
5,335
|
|
|
|
8
|
%
|
|
|
5,531
|
|
|
|
10
|
%
|
Orthopedic and Wound
|
|
|
1,878
|
|
|
|
3
|
%
|
|
|
65
|
|
|
|
0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Net Revenue
|
|
$
|
68,565
|
|
|
|
100
|
%
|
|
$
|
58,211
|
|
|
|
100
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Domestic
|
|
$
|
57,700
|
|
|
|
84
|
%
|
|
$
|
49,290
|
|
|
|
85
|
%
|
International
|
|
|
10,865
|
|
|
|
16
|
%
|
|
|
8,921
|
|
|
|
15
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Worldwide
|
|
$
|
68,565
|
|
|
|
100
|
%
|
|
$
|
58,211
|
|
|
|
100
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The increase in net revenue in fiscal 2010 compared to the
prior-year was primarily due to the following:
|
|
|
|
|
Incremental worldwide units sold increased revenue approximately
$6,291;
|
|
|
|
Ortho & Wound products increased revenue
$1,813; and
|
|
|
|
Higher average net selling prices primarily due to various
worldwide hospital list price increases for certain of our
products increased revenue by approximately $2,250.
|
The increase in worldwide units sold was primarily attributable
to the expansion of our direct sales force in the second half of
fiscal 2009, increased market acceptance of Veritas into the
worldwide hernia and general surgery markets and increased
market penetration of our microsurgery products.
We believe the expansion of our domestic direct sales force is a
key element of our long-term strategy to increase revenues. In
fiscal 2009, we expanded our direct sales force by 22 sales
representatives for a total of 65 sales representatives at the
end of fiscal 2009. In the first quarter of fiscal 2010, we
added eight direct sales representatives for our
Ortho & Wound products. As of October 31, 2010,
we have a total of 73 direct sales representatives in the U.S:
56 direct sales representatives sell our Veritas, Peri-Strips,
Tissue-Guard and Surgical tools and other products, nine direct
sales representatives sell our Microsurgery products and eight
direct sales representatives sell our Ortho & Wound
products.
In addition, for our Ortho & Wound products, we have
contracted with 16 independent representative groups (each with
multiple sales representatives) as of October 31, 2010.
This hybrid sales model of direct and independent sales
representatives presently provides sales coverage for
approximately three-fourths of the U.S. population. We
expect to appoint additional independent distributors in the
future to complete our coverage in the
U.S. Internationally, we have three independent
distributors serving Italy, Spain and Germany, and are presently
seeking to expand our European coverage through the appointment
of additional independent distributors.
We cannot fully assess the impact the current economic downturn
may have had on our results of operations during fiscal 2010. We
believe, however, that the volume of certain surgical procedures
in which
20
our products are used, particularly those which may be
considered elective, has been impacted by the current economic
downturn. In addition, we believe the financial condition of
certain of our hospital customers have been negatively impacted
by the economic downturn. These notable items, as well as other
factors, may have had an impact on our results of operations.
Revenue from Veritas patch products was $14,368 in fiscal 2010,
an increase of $5,611 or 64% from $8,757 in fiscal 2009. Veritas
revenue growth in fiscal 2010 was primarily driven by
incremental worldwide sales into the plastic and reconstructive
and general surgery markets. Additionally, late in the fourth
quarter of fiscal 2009, we received CE Mark approval for the use
of Veritas in hernia and breast reconstruction and commenced
selling Veritas to our European distributors. Higher average net
selling prices also contributed to the revenue increase in
fiscal 2010. Veritas is an extremely strong and conformable
biomaterial which acts as a scaffold that enables
rapid repopulation and revascularization by the surrounding host
tissue.
Worldwide net revenue from Peri-Strips was $19,414 in fiscal
2010, essentially flat as compared to revenue of $19,384 in
fiscal 2009. Increased average net selling prices were offset by
slightly lower units sold in fiscal 2010 as compared to fiscal
2009. Fiscal 2010 Peri-Strips revenue was also affected by the
impact of increased competition within the buttressing market.
Covidien, one of the two primary companies which offer surgical
staplers on which our Peri-Strips products are used, launched a
buttress product in mid-fiscal 2009 supplied integral with their
stapler cartridges. During fiscal 2010, worldwide revenue from
Peri-Strips products which are used with Covidien staplers
decreased 30% from fiscal 2009. This was offset by fiscal 2010
revenue for Peri-Strips products used with Ethicon staplers
increasing 20% from fiscal 2009. We are addressing the Covidien
competitive threat by highlighting the clinical history and
product performance of Peri-Strips through our expanded direct
sales force, seeking to convert additional non-buttressing
surgeons and continuing research activities to demonstrate the
benefits of Peri-Strips compared to other buttress products.
Peri-Strips are used to reduce risks and improve patient
outcomes in several procedures, with the predominant procedure
being gastric bypass surgery.
Revenue from Tissue-Guard patch products was $16,550 in fiscal
2010, an increase of $744 or 5% from $15,806 in fiscal 2009. The
fiscal 2010 increase was driven by a 3% increase in units sold
worldwide, in addition to slightly higher average selling prices
in the current year. Our Tissue-Guard family of products is used
to repair and replace damaged tissue in an array of surgical
procedures, including cardiac, vascular, thoracic, and
neurologic procedures.
Revenue from Microsurgery was $11,020 in fiscal 2010, an
increase of $2,352 or 27% from $8,668 in fiscal 2009. The
revenue growth was primarily driven by the fiscal 2009 expansion
of our sales force, increased market acceptance of the Coupler,
as well as the domestic market launch of the Flow
Coupler®
in the third quarter of fiscal 2010, resulting in a 24% increase
in Coupler unit sales in fiscal 2010. The Coupler is a device
used to connect extremely small arteries or veins, without
sutures, quickly, easily and with consistently excellent
results. The Flow Coupler enhances our Microsurgery product
offerings by combining our existing Coupler with Doppler
technology, enabling physicians to verify and monitor blood flow.
Revenue from Ortho & Wound products was $1,878 in
fiscal 2010 as compared to $65 from July to October 2009. Since
acquiring Ortho & Wound in July 2009, revenue from our
Ortho & Wound products has grown in each successive
quarter, primarily due to increased sales coverage in the
U.S. market. Our U.S. coverage has increased from
approximately 10% at the beginning of fiscal 2010 to
approximately 75% at the end of fiscal 2010, and our
Ortho & Wound hybrid sales force continue to develop
their sales territories and customer base by establishing
relationships with pre-acquisition customers as well as
prospecting for new customers. Our Ortho & Wound
products include the OrthADAPT Bioimplact and the Unite
Biomatrix. The OrthADAPT Bioimplant is used in numerous
orthopedic applications, including rotator cuff and Achilles
tendon repair, where there is a clinical need to reinforce the
repair. Unite Biomatrix provides a durable, collagen structure
that need be applied only once to a wound and maintains its
integrity while promoting wound healing.
Our gross margin increased by one-half of a percentage point to
72.3% in fiscal 2010 from 71.8% during fiscal 2009, due
primarily to increased sales from Veritas and higher average
list selling prices for certain of our products in fiscal 2010,
partially offset increased revenue from our Ortho &
Wound products, which have a lower gross margin than our other
products as well as lower manufacturing utilization in the
current year.
21
Factors which may affect the gross margin include product and
geographic mix of products sold, volume, product acquisitions
and disposals, and other production activities. Accordingly, our
gross margin may fluctuate from period to period based on
variations in these factors.
Selling, general and administrative (SG&A)
expense during fiscal 2010 was $37,812, an increase of $7,945 or
27% from SG&A expense of $29,867 in fiscal 2009. As a
percentage of net revenue, SG&A expense was 55% in fiscal
2010 as compared to 51% in the prior year. The SG&A expense
increase was due to $3,766 of incremental costs related to our
Ortho & Wound business, which was acquired in July
2009, as well as approximately $3,500 of incremental expense
related to the expansion of our direct sales force in the second
half of fiscal 2009. Additionally, stock-based compensation
expense was $1,455 (9 cents per diluted share) in fiscal 2010,
up from $937 (7 cents per diluted share) in fiscal 2009.
In fiscal 2011, we expect to incur higher SG&A expense as
compared to fiscal 2010 due to incremental investments we
believe are necessary to drive near and long-term revenue
growth. Such investments include increased sales and marketing
costs, higher clinical study activities and increased investment
in support of our Ortho & Wound business.
Research and development (R&D) expense totaled
$4,393 during fiscal 2010, an increase of $595 or 16% from
$3,798 in fiscal 2009. Fiscal 2010 activity focused on several
activities, including research to potentially expand the
indications of our Veritas product into new markets, providing
research and clinical data to support the use of Veritas in
various surgical procedures, exploring process improvements and
product enhancements for our proprietary tissue products,
comparative studies involving Peri-Strips and its competition,
advancing the technology of the Coupler and further development
of an orthopedic product and related instrumentation.
In fiscal 2011, we expect R&D expense to increase compared
to fiscal 2010 due to several activities, including research to
expand the size offerings and indications for use of our Veritas
product into new and existing markets, providing research and
clinical data to support the use of Veritas in various surgical
procedures, exploring additional process improvements and
product enhancements for our proprietary biomaterial products,
advancing the size offerings and technology of the Flow Coupler
and providing research and clinical data to support the launch
of the ProCuff product, an arthroscopically delivered
augmentation device for tendon repair, including rotator cuff
repair.
In fiscal 2009, we recorded other operating expenses of $4,100.
We expensed acquired in-process R&D costs of $3,500 related
to our acquisition of the assets of Pegasus, as it was
determined the related projects had no alternative future use.
We also recorded an impairment charge of $600 related to
identifiable intangible assets related to our fiscal 2007
acquisition of the
4Closuretm
Surgical Fascia Closure System (4Closure) following
an impairment analysis. This analysis was performed as a result
of a delay in the fiscal 2009 re-launch and re-brand of the
product, combined with actual revenues since acquisition not
meeting projected expectations. No other operating expenses were
recorded in fiscal 2010.
We recorded operating income of $7,335, an increase of $3,333 as
compared to operating income of $4,002 in fiscal 2009. The
increase in operating income in fiscal 2010 as compared to the
prior year was primarily driven by a reduction of other
operating costs of $4,100 (zero of these costs incurred in
fiscal 2010 while $4,100 incurred in fiscal 2009). In addition,
the operating loss related to our Ortho & Wound
business was approximately $4,100 higher in fiscal 2010 compared
to fiscal 2009 given a full year of operations in fiscal 2010,
with this higher operating loss largely offset by higher
operating profitability in our other operations. Interest income
was $284 in fiscal 2010 compared with $920 in fiscal 2009,
primarily due to significantly lower investment yields and lower
investment balances in the current year. Additionally in fiscal
2009, we sold our auction rate securities (ARS),
which had a par value of $9,000, for $7,650, realizing a loss on
sale of $1,350.
We recorded a provision for income taxes in fiscal 2010 of
$2,743 at an effective tax rate of 36%. We recorded income tax
expense of $866 in fiscal 2009 at an effective rate of 24.2% of
pretax income. Our fiscal 2009 effective tax rate was comprised
of a tax rate of 27.3% on operations and interest income and a
35.3% tax benefit on the capital loss of $1,350 incurred upon
the sale of our ARS. Our fiscal 2009 effective tax rate on
operations and interest income was lower than fiscal 2010 due to
lower pretax income in fiscal 2009 as
22
compared to fiscal 2010, higher permanent differences that
reduce taxes, and a lower overall rate for state taxes. As of
October 31, 2010, we recorded $367 in net current deferred
income tax assets and $2,139 in net long-term deferred income
tax assets.
Operating
Results Fiscal 2009 ($ in thousands except per share
data)
Net revenue increased 17% during fiscal 2009 to $58,211 from
$49,800 in fiscal 2008. Our operating income was $4,002 in
fiscal 2009, compared to $7,194 in the prior year. Net income
from continuing operations for fiscal 2009 was $2,706, or 23
cents per diluted share, compared to $6,165, or 48 cents per
diluted share during fiscal 2008.
The following table summarizes our net revenue by product group
and geography for fiscal 2009 and fiscal 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2009
|
|
|
2008
|
|
|
|
$
|
|
|
%
|
|
|
$
|
|
|
%
|
|
|
Veritas
|
|
$
|
8,757
|
|
|
|
15
|
%
|
|
$
|
4,468
|
|
|
|
9
|
%
|
Peri-Strips
|
|
|
19,384
|
|
|
|
33
|
%
|
|
|
17,653
|
|
|
|
35
|
%
|
Tissue-Guard
|
|
|
15,806
|
|
|
|
27
|
%
|
|
|
14,477
|
|
|
|
29
|
%
|
Microsurgery
|
|
|
8,668
|
|
|
|
15
|
%
|
|
|
7,749
|
|
|
|
16
|
%
|
Surgical Tools and other
|
|
|
5,531
|
|
|
|
10
|
%
|
|
|
5,453
|
|
|
|
11
|
%
|
Orthopedic and Wound
|
|
|
65
|
|
|
|
0
|
%
|
|
|
|
|
|
|
0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Net Revenue
|
|
$
|
58,211
|
|
|
|
100
|
%
|
|
$
|
49,800
|
|
|
|
100
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Domestic
|
|
$
|
49,290
|
|
|
|
85
|
%
|
|
$
|
42,190
|
|
|
|
85
|
%
|
International
|
|
|
8,921
|
|
|
|
15
|
%
|
|
|
7,610
|
|
|
|
15
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Worldwide
|
|
$
|
58,211
|
|
|
|
100
|
%
|
|
$
|
49,800
|
|
|
|
100
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The increase in net revenue in fiscal 2009 compared to the prior
year was primarily due to the following:
|
|
|
|
|
Incremental worldwide units sold (inclusive of new product
introductions) and product mix changes increased revenue
approximately $6,700; and
|
|
|
|
Higher average net selling prices primarily due to various
worldwide hospital list price increases for certain of our
products increased revenues by approximately $1,700.
|
The increase in worldwide units sold was primarily attributable
to our direct sales force, the expansion of our direct sales
force and increased market acceptance of Veritas into the
domestic hernia and general surgery markets.
Worldwide net revenue from Peri-Strips was $19,384 in fiscal
2009, an increase of 10% from $17,653 in fiscal 2008.
Peri-Strips growth rate exceeded the estimated growth of
procedures in which the product is used, which we believe was
attributable to product performance, our direct sales force
communicating the benefits of Peri-Strips, and the increased
international market penetration of PSD Veritas, partially
offset by increased competition. Peri-Strips are used to reduce
risks and improve patient outcomes in several procedures, with
the predominant procedure being gastric bypass surgery. Included
in the Peri-Strips product line was revenue from our two linear
products: PSD Veritas, our remodelable buttress, and PSD Apex,
our permanent buttress, as well as revenue from our PSD Veritas
Circular buttress.
We believe increased market acceptance of Peri-Strips has been
offset by the impact of increasing competition within the
buttressing market. Covidien, one of the two primary companies
which offer surgical staplers on which our Peri-Strips products
are used, launched a buttress product which is supplied integral
with their stapler cartridges in mid-fiscal 2009. During the
second half of fiscal 2009, worldwide revenue from Peri-Strips
products which are used with Covidien staplers decreased 24%
from the first half of fiscal 2009. This was partially offset by
revenue for Peri-Strips products used with another stapler
manufacturers products increasing 11%.
23
Revenue from Veritas patch products was $8,757 in fiscal 2009,
an increase of $4,289 or 96% from $4,468 in fiscal 2008. Veritas
revenue growth in fiscal 2009 was primarily driven by
incremental sales into the domestic plastic, reconstructive and
general surgery markets. Additionally, late in the fourth
quarter of fiscal 2009, we received CE Mark approval for the use
of Veritas in hernia and breast reconstruction.
Revenue from Tissue-Guard patch products was $15,806 in fiscal
2009, an increase of $1,329 or 9% from $14,477 in fiscal 2008.
The fiscal 2009 increase was driven by an 8% increase in units
sold worldwide.
Revenue from Microsurgery was $8,668 in fiscal 2009, an increase
of $919 or 12% from $7,749 in fiscal 2008. This revenue growth
was driven by Coupler unit sales growth in fiscal 2009 as well
as list price increases to the Coupler in late fiscal 2008.
Our gross margin increased three percentage points to 72% in
fiscal 2009 from 69% during fiscal 2008, due primarily to the
following factors:
|
|
|
|
|
Favorable sales mix (both product and geographic) benefited the
fiscal 2009 gross margin by nearly two percentage points.
|
|
|
|
Improved utilization of production resources in fiscal 2009
benefited the fiscal 2009 gross margin by nearly one
percentage point.
|
|
|
|
Higher average list selling prices for certain of our products
benefited the fiscal 2009 gross margin by approximately
one-half of one percentage point.
|
SG&A expense during fiscal 2009 was $29,867, an increase of
$6,165 or 26% from SG&A expense of $23,702 in fiscal 2008.
As a percentage of net revenue, SG&A expense was 51% in
fiscal 2009 as compared to 48% in the prior year. The SG&A
expense increase was due to the aforementioned expansion of our
direct sales force in fiscal 2009, $1,840 of operating expenses
related to the
start-up of
our newly acquired Ortho & Wound business, increased
legal expense as well as general and administrative investments
in new business development, clinical personnel and information
technology. Additionally, stock-based compensation expense was
$937 (7 cents per diluted share) in fiscal 2009, up from $509 (3
cents per diluted share) in fiscal 2008.
R&D expense totaled $3,798 during fiscal 2009, an increase
of $550 or 17% from the prior year, driven by increased project
activity during the current year. Fiscal 2009 activity focused
on several areas, including research to support current
indications for use of Veritas, exploring potential
opportunities for further expanding the indications for use of
Veritas, improving the delivery system for our Peri-Strips
products and advancing the technology of the Coupler, among
others.
In fiscal 2009, we recorded other operating expenses of $4,100.
We expensed acquired in-process R&D costs of $3,500 related
to our acquisition of the assets of Pegasus, as it was
determined the related projects had no alternative future use.
We also recorded an impairment charge of $600 related to
identifiable intangible assets related to our fiscal 2007
acquisition of 4Closure following an impairment analysis. This
analysis was performed as a result of a delay in the fiscal 2009
re-launch and re-brand of the product, combined with actual
revenues since acquisition not meeting projected expectations.
No such other operating expenses were recorded in fiscal 2008.
We recorded operating income from continuing operations of
$4,002 in fiscal 2009, a decrease of $3,192 compared to
operating income of $7,194 in fiscal 2008. Interest income was
$920 in fiscal 2009 compared with $2,077 in fiscal 2008, with
the fiscal 2009 decrease primarily due to lower investment
yields. Additionally in fiscal 2009, we sold our auction rate
securities (ARS), which had a par value of $9,000,
for $7,650, realizing a loss on sale of $1,350.
We recorded income tax expense of $866 in fiscal 2009 at an
effective rate of 24.2% of pretax income. Our fiscal 2009
effective tax rate was comprised of a tax rate of 27.3% on
operations and interest income and a 35.3% tax benefit on the
capital loss of $1,350 incurred upon the sale of our ARS. In
fiscal 2008, we recorded income tax expense of $3,106 at an
effective rate of 33.5% on continuing operations. Our fiscal
2009 effective tax rate on operations and interest income was
lower than the prior-year due to a decrease in pretax income in
fiscal 2009 as compared to fiscal 2008, higher permanent
differences that reduce taxes, and a lower overall rate for
state taxes. The lower state tax rate was primarily due to a
change in state apportionment
24
factors caused by the current expected mix of our product sales
by state. As of October 31, 2009, we recorded $367 in net
current deferred income tax assets and $2,022 in net long-term
deferred income tax assets.
During fiscal 2008, we recorded a net gain on sale of our
interventional business of $5,340 which reflected a pre-tax gain
of $11,423 and a tax provision of $6,083. Approximately $4,100
of book basis goodwill had a tax basis of $0, thereby resulting
in a higher gain for tax purposes. Additionally in fiscal 2008,
we recorded a net loss related to our discontinued operations of
$20. Included within the net loss from discontinued operations
was an operating loss of $30 and a benefit from income taxes of
$10.
Liquidity
and Capital Resources ($ in thousands)
Cash, cash equivalents and investments totaled $61,924 as of
October 31, 2010, an increase of $1,175 as compared to
cash, cash equivalents, investments and restricted cash of
$60,749 as of October 31, 2009. Included in the above, we
have $7,854 of investments classified as non-current as of
October 31, 2010. Working capital at October 31, 2010
and 2009 was $66,271 and $63,885, respectively. We have no
long-term debt. We currently expect our cash on hand and cash
from operations to be sufficient to cover both our short- and
long-term operating requirements, subject however, to numerous
variables, including acquisition opportunities, research and
development priorities and the growth and profitability of the
business.
The increase in cash, cash equivalents and investments in fiscal
2010 was primarily due to cash provided by operating activities
of $7,115 in fiscal 2010. This was partially offset by the use
of $5,101 to repurchase 385,836 shares of our common stock
in fiscal 2010.
Operating activities provided cash of $7,115 in fiscal 2010, as
compared to providing cash of $9,794 during fiscal 2009. The
fiscal 2010 cash provided by operating activities was driven by
net income of $4,876 and $5,565 in non-cash expenses. Working
capital changes used cash of $3,326 in fiscal 2010, driven by
$1,963 cash used for increased accounts receivable and $1,709
cash used for increased inventories to support higher revenue
levels. The fiscal 2009 cash provided by operating activities
was driven by net income of $2,706, which included $6,986 in
non-cash expenses, with the most significant of these non-cash
items being $3,500 in acquired in-process R&D expense and
the $1,350 loss on ARS sale. Working capital changes provided
cash of $102 in fiscal 2009, driven by increased accrued income
taxes of $2,085, partially offset by $953 in cash used for
increased accounts receivable to support higher revenue levels.
Investing activities used cash of $7,006 during fiscal 2010, due
primarily to using cash of $5,779 towards the net purchase of
short- and long-term investments during the year. We also used
$1,102 for purchases of property, plant and equipment in fiscal
2010. Investing activities used cash of $30,786 during fiscal
2009, as we used $19,821 towards the net purchase of short- and
long-term investments, $12,319 for the acquisition of
substantially all of the assets of Pegasus Biologics, Inc., and
$1,156 for the purchase of property, plant and equipment.
Financing activities used cash of $3,021 during fiscal 2010, as
compared to using cash of $10,040 in fiscal 2009. In fiscal
2010, $5,101 of cash was used to repurchase 385,836 shares
of common stock, partially offset by $2,080 of proceeds from
equity-based compensation plans. During fiscal 2009, $11,018 of
cash was used to repurchase 716,237 shares of common stock,
partially offset by $978 of proceeds from equity-based
compensation plans.
In October 2009, we sold our ARS, which had a par value of
$9,000, for $7,650, recording a loss on sale of $1,350. Should a
regulatory or other settlement occur during the 24 months
subsequent to the date of ARS sale in which the Company would
have otherwise been eligible to tender any of its ARS, the
Company will be entitled to an additional payment of the amount
the Company would have received in such settlement that is in
excess of the amount of sales proceeds received by the Company
up to the securities par value.
The following table summarizes our contractual obligations and
operating leases. For more information, see Note 9 to our
Consolidated Financial Statements. Our commitments under these
obligations are as follows for the fiscal year ending October 31:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
< 1 Year
|
|
1-3 Years
|
|
3-5 Years
|
|
5 < Years
|
|
Total
|
|
Operating leases
|
|
$
|
1,020
|
|
|
$
|
1,720
|
|
|
$
|
121
|
|
|
$
|
|
|
|
$
|
2,861
|
|
25
Inflation
We believe inflation has not had a material effect on our
operations or financial condition.
Foreign
Currency Transactions
Substantially all of our foreign transactions are negotiated,
invoiced and paid in U.S. dollars. Fluctuations in currency
exchange rates in other countries may therefore influence the
demand for our products by changing the price of our products as
denominated in the currency of the countries in which the
products are sold.
Critical
Accounting Policies
Investments: Our investments consist of
taxable and tax-exempt commercial paper, treasury and agency
securities, corporate bond and municipal bond investments. Our
investment policy seeks to manage these assets to achieve our
goal of preserving principal, maintaining adequate liquidity at
all times, and maximizing returns subject to our investment
guidelines. We account for all of our investments as
available-for-sale
and report these investments at fair value, with unrealized
gains and losses excluded from earnings and reported in
Accumulated Other Comprehensive Income, a component
of shareholders equity.
We review our investments for impairment to determine the
classification of the impairment as temporary or
other-than-temporary.
A temporary impairment charge results in an unrealized loss
being recorded in the other comprehensive income component of
shareholders equity. Such unrealized loss does not reduce
net income for the applicable accounting period because the loss
is not viewed as
other-than-temporary.
Accounts Receivable: Credit is extended based
on evaluation of a customers financial condition,
historical sales and payment history. Generally, collateral is
not required. Accounts receivable are generally due within
30-90 days
and are stated at amounts due from customers net of an allowance
for doubtful accounts. Accounts receivable outstanding longer
than the contractual payment terms are considered past due. We
determine our allowance for doubtful accounts by considering a
number of factors, including the length of time trade accounts
receivable are past due, our previous loss history, the
customers current ability to pay its obligation to us, and
the condition of the general economy and the industry as a
whole. We write off accounts receivable when they become
uncollectible, and payments subsequently received on such
receivables are credited to the allowance for doubtful accounts.
Indefinite-lived Intangible Assets: Our
indefinite-lived intangible assets consist of goodwill, which is
carried at cost. Indefinite-lived intangible assets are not
amortized, but are required to be reviewed annually for
impairment, and between annual test dates in certain
circumstances. We perform our annual impairment test for
goodwill in the fourth quarter of each fiscal year, or more
often as circumstances require. In assessing the recoverability
of goodwill, estimates of market capitalization and other
factors are made to determine the fair value of the respective
assets. If these estimates change in the future, we may be
required to record impairment charges for these assets.
Recoverability is assessed by comparison of the fair value of
the Company to its carrying amount to determine if there is
potential impairment. If the fair value of the Company is less
than its carrying value, an impairment loss is recorded to the
extent that the fair value of the goodwill within the Company is
less than its carrying value. If the carrying amount of the
goodwill exceeds their fair value, an impairment loss is
recognized.
Definite-lived Intangible
Assets: Definite-lived intangible assets consist
of patents, trademarks, developed technology, non-competes and
licenses, which are carried at amortized cost. We review our
definite-lived intangible assets whenever events or
circumstances indicate that the carrying amount of an asset may
not be recoverable. We assess recoverability by reference to
future cash flows from the products underlying these intangible
assets. If these estimates change in the future, we may be
required to record impairment charges for these assets.
Revenue Recognition: We recognize revenue when
the product has been shipped to the customer if there is
evidence that the customer has agreed to purchase the products,
delivery and performance have occurred, the price and terms of
sale are fixed and collection of the receivable is expected.
Less than five percent of our revenue is derived from consigned
inventory, for which we recognize revenue upon customer use and
receipt of proper purchase order
and/or
purchase requisition documentation. All amounts billed to
customers in a sales
26
transaction related to shipping and handling are classified as
revenue. Our sales policy does not allow sales returns.
Inventories: Inventories, which are comprised
of raw materials, work in process and finished goods, are valued
at the lower of cost,
first-in,
first-out (FIFO) or market. Overhead costs are
applied to work in process and finished goods based on annual
estimates of production volumes and overhead spending. These
estimates are reviewed and assessed for reasonableness on a
quarterly basis and adjusted as needed. The estimated value of
excess, slow-moving and obsolete inventory, as well as inventory
with a carrying value in excess of its net realizable value, is
established on a quarterly basis through review of inventory on
hand and assessment of future product demand, anticipated
release of new products into the market, historical experience
and product expiration.
Stock-Based Compensation: We recognize
stock-based compensation based on certain assumptions within the
Black-Scholes Model. These assumptions are used to determine an
estimated fair value of stock based payment awards on the date
of grant and require subjective judgment. Because employee stock
options have characteristics significantly different from those
of traded options, and because changes in the assumptions can
materially affect the fair value estimate, the existing models
may not provide a reliable single measure of the fair value of
the employee stock options. We assess the assumptions and
methodologies used to calculate the estimated fair value of
stock-based compensation on a regular basis. Circumstances may
change and additional data may become available over time, which
could result in changes to these assumptions and methodologies
and thereby materially impact our fair value determination.
Income Taxes: We account for income taxes
using the asset and liability method. The asset and liability
method provides that deferred tax assets and liabilities are
recorded based on the differences between the tax basis of
assets and liabilities and their carrying amounts for financial
reporting purposes (temporary differences). Deferred
tax assets are reduced by a valuation allowance, when, in the
opinion of management, it is more likely than not that some
portion or all of the deferred tax assets will not be realized.
We recognize the financial statement benefit of a tax position
only after determining that the relevant tax authority would
more likely than not sustain the position following an audit.
For tax positions meeting the more-likely-than-not threshold,
the amount recognized in the financial statements is the largest
benefit that has a greater than 50 percent likelihood of
being realized upon ultimate settlement with the relevant tax
authority.
|
|
Item 7A
|
Quantitative
and Qualitative Disclosures about Market Risk
|
We maintain financial instruments in cash and cash equivalents,
investments and accounts receivable. We believe that the
interest rate, credit and market risk related to these accounts
is not significant. We manage the risk associated with these
accounts through periodic reviews of the carrying value for
non-collectability of assets and establishment of appropriate
allowances in connection with our internal controls and
policies. We may enter into derivative instruments or perform
hedging activities. However, our policy is to only enter into
contracts that can be designated as normal purchases or sales.
27
|
|
Item 8
|
Financial
Statements and Supplementary Data
|
REPORTS
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Board of Directors and Shareholders
Synovis Life Technologies, Inc.
We have audited the accompanying consolidated balance sheets of
Synovis Life Technologies, Inc. and Subsidiaries (the
Company) as of October 31, 2010 and 2009, and
the related consolidated statements of income,
shareholders equity, and cash flows for each of the three
years in the period ended October 31, 2010. Our audits of
the basic consolidated financial statements included the
financial statement schedule listed in the index appearing under
Item 15. These financial statements and financial statement
schedule are the responsibility of the Companys
management. Our responsibility is to express an opinion on these
financial statements and financial statement schedule based on
our audits.
We conducted our audits in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are
free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the
accounting principles used and significant estimates made by
management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred
to above present fairly, in all material respects, the financial
position of Synovis Life Technologies, Inc. and Subsidiaries as
of October 31, 2010 and 2009, and the results of their
operations and their cash flows for each of the three years in
the period ended October 31, 2010 in conformity with
accounting principles generally accepted in the United States of
America. Also in our opinion, the related financial statement
schedule, when considered in relation to the basic consolidated
financial statements taken as a whole, presents fairly, in all
material respects, the information set forth therein.
We also have audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States),
Synovis Life Technologies, Inc. and Subsidiaries internal
control over financial reporting as of October 31, 2010,
based on criteria established in Internal Control
Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO) and our
report dated January 5, 2011 expressed an unqualified
opinion on the effectiveness of the Companys internal
control over financial reporting.
Minneapolis, Minnesota
January 5, 2011
28
Board of Directors and Shareholders
Synovis Life Technologies, Inc.
We have audited Synovis Life Technologies, Inc. and
Subsidiaries (the Company) internal control
over financial reporting as of October 31, 2010, based on
criteria established in Internal Control
Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO). The
Companys management is responsible for maintaining
effective internal control over financial reporting and for its
assessment of the effectiveness of internal control over
financial reporting, included in the accompanying
Managements Report on Internal Control Over Financial
Reporting. Our responsibility is to express an opinion on the
Companys internal control over financial reporting based
on our audit.
We conducted our audit in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether effective internal control
over financial reporting was maintained in all material
respects. Our audit included obtaining an understanding of
internal control over financial reporting, assessing the risk
that a material weakness exists, testing and evaluating the
design and operating effectiveness of internal control based on
the assessed risk, and performing such other procedures as we
considered necessary in the circumstances. We believe that our
audit provides a reasonable basis for our opinion.
A companys internal control over financial reporting is a
process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with
generally accepted accounting principles. A companys
internal control over financial reporting includes those
policies and procedures that (1) pertain to the maintenance
of records that, in reasonable detail, accurately and fairly
reflect the transactions and dispositions of the assets of the
company; (2) provide reasonable assurance that transactions
are recorded as necessary to permit preparation of financial
statements in accordance with generally accepted accounting
principles, and that receipts and expenditures of the company
are being made only in accordance with authorizations of
management and directors of the company; and (3) provide
reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use, or disposition of the
companys assets that could have a material effect on the
financial statements.
Because of its inherent limitations, internal control over
financial reporting may not prevent or detect misstatements.
Also, projections of any evaluation of effectiveness to future
periods are subject to the risk that controls may become
inadequate because of changes in conditions, or that the degree
of compliance with the policies or procedures may deteriorate.
In our opinion, Synovis Life Technologies, Inc. and Subsidiaries
maintained, in all material respects, effective internal control
over financial reporting as of October 31, 2010, based on
criteria established in Internal Control
Integrated Framework issued by COSO.
We also have audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States), the
consolidated balance sheets of Synovis Life Technologies, Inc.
and Subsidiaries as of October 31, 2010 and 2009, and the
related consolidated statements of income, shareholders
equity, and cash flows and financial statement schedule for each
of the three years in the period ended October 31, 2010,
and our report dated January 5, 2011 expressed an
unqualified opinion on those consolidated financial statements
and financial statement schedule.
Minneapolis, Minnesota
January 5, 2011
29
SYNOVIS
LIFE TECHNOLOGIES, INC.
CONSOLIDATED
STATEMENTS OF INCOME
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Fiscal Years Ended October 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
|
(In thousands, except
|
|
|
|
per share data)
|
|
|
Net revenue
|
|
$
|
68,565
|
|
|
$
|
58,211
|
|
|
$
|
49,800
|
|
Cost of revenue
|
|
|
19,025
|
|
|
|
16,444
|
|
|
|
15,656
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross margin
|
|
|
49,540
|
|
|
|
41,767
|
|
|
|
34,144
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative
|
|
|
37,812
|
|
|
|
29,867
|
|
|
|
23,702
|
|
Research and development
|
|
|
4,393
|
|
|
|
3,798
|
|
|
|
3,248
|
|
Other
|
|
|
|
|
|
|
4,100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses
|
|
|
42,205
|
|
|
|
37,765
|
|
|
|
26,950
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
7,335
|
|
|
|
4,002
|
|
|
|
7,194
|
|
Interest income
|
|
|
284
|
|
|
|
920
|
|
|
|
2,077
|
|
Loss on sale of investments
|
|
|
|
|
|
|
(1,350
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before provision for income
taxes
|
|
|
7,619
|
|
|
|
3,572
|
|
|
|
9,271
|
|
Provision for income taxes
|
|
|
2,743
|
|
|
|
866
|
|
|
|
3,106
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income from continuing operations
|
|
|
4,876
|
|
|
|
2,706
|
|
|
|
6,165
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Discontinued operations:
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations of discontinued business, net of tax
benefit of $10
|
|
|
|
|
|
|
|
|
|
|
(20
|
)
|
Gain on sale of discontinued operations, net of taxes of $6,083
|
|
|
|
|
|
|
|
|
|
|
5,340
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
4,876
|
|
|
$
|
2,706
|
|
|
$
|
11,485
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations
|
|
$
|
0.43
|
|
|
$
|
0.23
|
|
|
$
|
0.50
|
|
Discontinued operations
|
|
|
|
|
|
|
|
|
|
|
0.43
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per share
|
|
$
|
0.43
|
|
|
$
|
0.23
|
|
|
$
|
0.93
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations
|
|
$
|
0.43
|
|
|
$
|
0.23
|
|
|
$
|
0.48
|
|
Discontinued operations
|
|
|
|
|
|
|
|
|
|
|
0.42
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share
|
|
$
|
0.43
|
|
|
$
|
0.23
|
|
|
$
|
0.90
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
11,262
|
|
|
|
11,588
|
|
|
|
12,395
|
|
Diluted
|
|
|
11,441
|
|
|
|
11,827
|
|
|
|
12,721
|
|
The accompanying notes are an integral part of these
consolidated financial statements
30
SYNOVIS
LIFE TECHNOLOGIES, INC.
CONSOLIDATED
BALANCE SHEETS
|
|
|
|
|
|
|
|
|
|
|
As of October 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
|
(In thousands, except share and per
|
|
|
|
share data)
|
|
|
ASSETS
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
12,951
|
|
|
$
|
15,863
|
|
Short-term investments
|
|
|
41,119
|
|
|
|
38,960
|
|
Accounts receivable, net
|
|
|
8,701
|
|
|
|
6,925
|
|
Inventories
|
|
|
9,433
|
|
|
|
7,724
|
|
Deferred income tax asset, net
|
|
|
367
|
|
|
|
367
|
|
Other current assets
|
|
|
1,715
|
|
|
|
1,755
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
74,286
|
|
|
|
71,594
|
|
|
|
|
|
|
|
|
|
|
Investments, net
|
|
|
7,854
|
|
|
|
5,926
|
|
Property, plant and equipment, net
|
|
|
3,401
|
|
|
|
3,719
|
|
Goodwill
|
|
|
3,620
|
|
|
|
3,618
|
|
Other intangible assets, net
|
|
|
6,182
|
|
|
|
6,841
|
|
Deferred income tax asset, net
|
|
|
2,139
|
|
|
|
2,022
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
97,482
|
|
|
$
|
93,720
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS EQUITY
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
1,644
|
|
|
$
|
1,962
|
|
Accrued expenses
|
|
|
6,371
|
|
|
|
5,747
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
8,015
|
|
|
|
7,709
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
8,015
|
|
|
|
7,709
|
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies (Note 9)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders equity:
|
|
|
|
|
|
|
|
|
Preferred stock: authorized 5,000,000 shares of
$0.01 par value; none issued or outstanding as of
October 31, 2010 and 2009
|
|
|
|
|
|
|
|
|
Common stock: authorized 20,000,000 shares of
$0.01 par value; issued and outstanding, 11,228,654 and
11,398,874 as of October 31, 2010 and 2009, respectively
|
|
|
112
|
|
|
|
114
|
|
Additional paid-in capital
|
|
|
61,780
|
|
|
|
63,132
|
|
Accumulated other comprehensive income
|
|
|
26
|
|
|
|
92
|
|
Retained earnings
|
|
|
27,549
|
|
|
|
22,673
|
|
|
|
|
|
|
|
|
|
|
Total shareholders equity
|
|
|
89,467
|
|
|
|
86,011
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and shareholders equity
|
|
$
|
97,482
|
|
|
$
|
93,720
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these
consolidated financial statements
31
SYNOVIS
LIFE TECHNOLOGIES, INC.
CONSOLIDATED
STATEMENTS OF SHAREHOLDERS EQUITY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
Common Stock
|
|
|
Paid-In
|
|
|
Comprehensive
|
|
|
Retained
|
|
|
|
|
|
|
Shares
|
|
|
Par Value
|
|
|
Capital
|
|
|
Income (Loss)
|
|
|
Earnings
|
|
|
Total
|
|
|
|
(In thousands, except share data)
|
|
|
Balance as of October 31, 2007
|
|
|
12,359,302
|
|
|
$
|
124
|
|
|
$
|
78,347
|
|
|
$
|
|
|
|
$
|
8,482
|
|
|
$
|
86,953
|
|
Stock option exercises, including tax benefit
|
|
|
158,635
|
|
|
|
1
|
|
|
|
1,789
|
|
|
|
|
|
|
|
|
|
|
|
1,790
|
|
Employee Stock Purchase Plan activity
|
|
|
4,900
|
|
|
|
|
|
|
|
80
|
|
|
|
|
|
|
|
|
|
|
|
80
|
|
Repurchase of the Companys common stock
|
|
|
(504,167
|
)
|
|
|
(5
|
)
|
|
|
(8,544
|
)
|
|
|
|
|
|
|
|
|
|
|
(8,549
|
)
|
Stock-based compensation expense
|
|
|
|
|
|
|
|
|
|
|
509
|
|
|
|
|
|
|
|
|
|
|
|
509
|
|
Comprehensive Income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net unrealized loss on investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2,407
|
)
|
|
|
|
|
|
|
(2,407
|
)
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,485
|
|
|
|
11,485
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,078
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of October 31, 2008
|
|
|
12,018,670
|
|
|
|
120
|
|
|
|
72,181
|
|
|
|
(2,407
|
)
|
|
|
19,967
|
|
|
|
89,861
|
|
Stock option exercises, including tax benefit
|
|
|
89,376
|
|
|
|
1
|
|
|
|
927
|
|
|
|
|
|
|
|
|
|
|
|
928
|
|
Employee Stock Purchase Plan activity
|
|
|
7,065
|
|
|
|
|
|
|
|
98
|
|
|
|
|
|
|
|
|
|
|
|
98
|
|
Repurchase of the Companys common stock
|
|
|
(716,237
|
)
|
|
|
(7
|
)
|
|
|
(11,011
|
)
|
|
|
|
|
|
|
|
|
|
|
(11,018
|
)
|
Stock-based compensation expense
|
|
|
|
|
|
|
|
|
|
|
937
|
|
|
|
|
|
|
|
|
|
|
|
937
|
|
Comprehensive Income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net unrealized gain on investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,499
|
|
|
|
|
|
|
|
2,499
|
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,706
|
|
|
|
2,706
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,205
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of October 31, 2009
|
|
|
11,398,874
|
|
|
|
114
|
|
|
|
63,132
|
|
|
|
92
|
|
|
|
22,673
|
|
|
|
86,011
|
|
Stock option exercises, including tax benefit
|
|
|
204,807
|
|
|
|
2
|
|
|
|
2,140
|
|
|
|
|
|
|
|
|
|
|
|
2,142
|
|
Employee Stock Purchase Plan activity
|
|
|
10,809
|
|
|
|
|
|
|
|
150
|
|
|
|
|
|
|
|
|
|
|
|
150
|
|
Repurchase of the Companys common stock
|
|
|
(385,836
|
)
|
|
|
(4
|
)
|
|
|
(5,097
|
)
|
|
|
|
|
|
|
|
|
|
|
(5,101
|
)
|
Stock-based compensation expense
|
|
|
|
|
|
|
|
|
|
|
1,455
|
|
|
|
|
|
|
|
|
|
|
|
1,455
|
|
Comprehensive Income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net unrealized loss on investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(66
|
)
|
|
|
|
|
|
|
(66
|
)
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,876
|
|
|
|
4,876
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,810
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of October 31, 2010
|
|
|
11,228,654
|
|
|
$
|
112
|
|
|
$
|
61,780
|
|
|
$
|
26
|
|
|
$
|
27,549
|
|
|
$
|
89,467
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these
consolidated financial statements
32
SYNOVIS
LIFE TECHNOLOGIES, INC.
CONSOLIDATED
STATEMENTS OF CASH FLOWS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Fiscal Years Ended
|
|
|
|
October 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
|
(In thousands)
|
|
|
CASH FLOWS FROM OPERATING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
4,876
|
|
|
$
|
2,706
|
|
|
$
|
11,485
|
|
Adjustments to reconcile net income to net cash provided by
operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization of property, plant and equipment
|
|
|
1,228
|
|
|
|
1,017
|
|
|
|
1,897
|
|
Amortization of intangible assets
|
|
|
782
|
|
|
|
539
|
|
|
|
462
|
|
Amortization of investment premium, net
|
|
|
1,626
|
|
|
|
1,027
|
|
|
|
187
|
|
Loss on sale or disposal of property, plant and equipment
|
|
|
192
|
|
|
|
25
|
|
|
|
10
|
|
Provision for uncollectible accounts
|
|
|
204
|
|
|
|
149
|
|
|
|
134
|
|
Stock-based compensation
|
|
|
1,455
|
|
|
|
937
|
|
|
|
509
|
|
Tax benefit from stock option exercises
|
|
|
212
|
|
|
|
48
|
|
|
|
145
|
|
Gain on sale of interventional business
|
|
|
|
|
|
|
|
|
|
|
(5,340
|
)
|
Acquired in-process research and development expense
|
|
|
|
|
|
|
3,500
|
|
|
|
|
|
Loss on sale of investments
|
|
|
|
|
|
|
1,350
|
|
|
|
|
|
Impairment of intangible assets
|
|
|
|
|
|
|
600
|
|
|
|
|
|
Deferred income taxes
|
|
|
(117
|
)
|
|
|
(2,206
|
)
|
|
|
644
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
(1,980
|
)
|
|
|
(953
|
)
|
|
|
(627
|
)
|
Inventories
|
|
|
(1,709
|
)
|
|
|
62
|
|
|
|
(634
|
)
|
Other current assets
|
|
|
40
|
|
|
|
677
|
|
|
|
(1,447
|
)
|
Accounts payable
|
|
|
(318
|
)
|
|
|
637
|
|
|
|
(381
|
)
|
Accrued expenses
|
|
|
624
|
|
|
|
(321
|
)
|
|
|
(5,623
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities
|
|
|
7,115
|
|
|
|
9,794
|
|
|
|
1,421
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM INVESTING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase of property, plant and equipment
|
|
|
(1,102
|
)
|
|
|
(1,156
|
)
|
|
|
(990
|
)
|
Investments in identifiable intangible assets
|
|
|
(123
|
)
|
|
|
(105
|
)
|
|
|
(46
|
)
|
Purchase of assets of Pegasus Biologics, Inc.
|
|
|
|
|
|
|
(12,319
|
)
|
|
|
|
|
Purchases of investments
|
|
|
(79,397
|
)
|
|
|
(43,226
|
)
|
|
|
(60,019
|
)
|
Redemptions of investments
|
|
|
73,618
|
|
|
|
23,405
|
|
|
|
76,582
|
|
Proceeds from sale of interventional business
|
|
|
|
|
|
|
|
|
|
|
30,440
|
|
Decrease (increase) in restricted cash
|
|
|
|
|
|
|
2,950
|
|
|
|
(2,950
|
)
|
Other
|
|
|
(2
|
)
|
|
|
(335
|
)
|
|
|
(297
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash (used in) provided by investing activities
|
|
|
(7,006
|
)
|
|
|
(30,786
|
)
|
|
|
42,720
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM FINANCING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net proceeds related to stock-based compensation plans
|
|
|
1,996
|
|
|
|
823
|
|
|
|
1,429
|
|
Repurchase of the Companys common stock
|
|
|
(5,101
|
)
|
|
|
(11,018
|
)
|
|
|
(8,549
|
)
|
Excess tax benefit of stock option exercises
|
|
|
84
|
|
|
|
155
|
|
|
|
296
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in financing activities
|
|
|
(3,021
|
)
|
|
|
(10,040
|
)
|
|
|
(6,824
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net change in cash and cash equivalents
|
|
|
(2,912
|
)
|
|
|
(31,032
|
)
|
|
|
37,317
|
|
Cash and cash equivalents at beginning of year
|
|
|
15,863
|
|
|
|
46,895
|
|
|
|
9,578
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of year
|
|
$
|
12,951
|
|
|
$
|
15,863
|
|
|
$
|
46,895
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these
consolidated financial statements
33
SYNOVIS
LIFE TECHNOLOGIES, INC.
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
|
|
1.
|
Business
Description and Summary of Significant Accounting Policies (in
thousands):
|
Synovis Life Technologies, Inc. develops, manufactures and
markets biological and mechanical products used by several
surgical specialties for the repair of soft tissue damaged or
destroyed by disease or injury. Our products are designed to
reduce risks
and/or
facilitate critical surgeries, improve patient outcomes and
reduce healthcare costs. Our products serve a wide array of
medical markets, including general surgery, bariatric, vascular,
cardiac, thoracic, neurological, microsurgery, orthopedic and
woundcare.
As discussed in Note 3 to our consolidated financial
statements, we completed the sale of substantially all of the
assets of our interventional business on January 31, 2008.
The pre-tax gain on the sale totaled $11,423. Income taxes
recorded on the gain were $6,083, resulting in a net gain of
$5,340. We also recorded a net loss related to the operation of
discontinued operations in fiscal 2008 of $20.
Basis of Consolidation: The consolidated
financial statements include the accounts of Synovis Life
Technologies, Inc. and its wholly owned subsidiaries, after
elimination of intercompany accounts and transactions.
Use of Estimates: The preparation of
consolidated financial statements in conformity with Generally
Accepted Accounting Principles (GAAP) in the United
States of America requires management to make estimates and
assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities
at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting periods. Actual
results could differ from those estimates.
Cash and Cash Equivalents: Cash and cash
equivalents consist of cash and highly liquid investments
purchased with an original maturity of three months or less when
purchased. These investments are carried at cost, which
approximates fair value. Cash amounts typically are in excess of
federally insured limits.
Investments: Our investments consist of
taxable and tax-exempt commercial paper, treasury and agency
securities, corporate bond and municipal bond investments. Our
investment policy seeks to manage these assets to achieve our
goal of preserving principal, maintaining adequate liquidity at
all times, and maximizing returns subject to our investment
guidelines. We account for all of our investments as
available-for-sale
and report these investments at fair value, with unrealized
gains and losses excluded from earnings and reported in
Accumulated Other Comprehensive Income, a component
of shareholders equity.
We review our investments for impairment to determine the
classification of the impairment as temporary or
other-than-temporary.
A temporary impairment charge results in an unrealized loss
being recorded in the other comprehensive income component of
shareholders equity. Such unrealized loss does not reduce
net income for the applicable accounting period because the loss
is not viewed as
other-than-temporary.
Accounts Receivable: Credit is extended based
on evaluation of a customers financial condition,
historical sales and payment history. Generally, collateral is
not required. Accounts receivable are generally due within 30 to
90 days and are stated at amounts due from customers net of
an allowance for doubtful accounts. Accounts receivable
outstanding longer than the contractual payment terms are
considered past due. We determine our allowance for doubtful
accounts by considering a number of factors, including the
length of time trade accounts receivable are past due, our
previous loss history, the customers current ability to
pay its obligation to us, and the condition of the general
economy and the industry as a whole. We write off accounts
receivable when they become uncollectible, and payments
subsequently received on such receivables are credited to the
allowance for doubtful accounts.
Inventories: Inventories, which are comprised
of raw materials, work in process and finished goods, are valued
at the lower of cost,
first-in,
first-out (FIFO) or market. Overhead costs are
applied to work in process and finished goods based on annual
estimates of production volume and overhead spending. These
estimates are reviewed and assessed for reasonableness on a
quarterly basis and adjusted if so needed. The estimated value
of excess, slow-moving and obsolete inventory as well as
inventory with a carrying value in excess of its net
34
SYNOVIS
LIFE TECHNOLOGIES, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
realizable value is established on a quarterly basis through
review of inventory on hand and assessment of future product
demand, anticipated release of new products into the market,
historical experience and product expiration.
Property, Plant and Equipment: Property, plant
and equipment are stated at cost, net of accumulated
depreciation and amortization. Depreciation and amortization are
calculated using the straight-line method over the estimated
useful lives of the related assets. Furniture, fixtures and
computer equipment are depreciated over a 3 to 7 year life,
and manufacturing equipment is depreciated over a 5 to
10 year life. Amortization of leasehold improvements is
recorded on a straight-line basis over the life of the related
facility leases or the estimated useful life of the assets,
whichever is shorter. Major replacements and improvements are
capitalized and maintenance and repairs, which do not improve or
extend the useful lives of the respective assets, are charged to
operations. The asset and related accumulated depreciation or
amortization accounts are adjusted for asset retirements and
disposals with the resulting gain or loss, if any, recorded in
the Consolidated Statements of Income at the time of disposal.
Our long-lived depreciable assets are reviewed for impairment
whenever events or changes in circumstances indicate that the
carrying amount of the asset in question may not be recoverable.
Impairment losses are recorded whenever the fair value of the
asset is determined to be lower than its carrying amount.
Indefinite-lived Intangible Assets: Our
indefinite-lived intangible assets consist of goodwill, which is
carried at cost. Indefinite-lived intangible assets are not
amortized, but are required to be reviewed annually for
impairment, and between annual test dates in certain
circumstances. We perform our annual impairment test for
goodwill in the fourth quarter of each fiscal year, or more
often as circumstances require. In assessing the recoverability
of goodwill, estimates of market capitalization and other
factors are made to determine the fair value of the respective
assets. If these estimates change in the future, we may be
required to record impairment charges for these assets.
Recoverability is assessed by comparison of the fair value of
the Company to its carrying amount to determine if there is
potential impairment. If the fair value of the Company is less
than its carrying value, an impairment loss is recorded to the
extent that the fair value of the goodwill within the Company is
less than its carrying value. If the carrying amount of the
goodwill exceeds their fair value, an impairment loss is
recognized.
Definite-lived Intangible
Assets: Definite-lived intangible assets consist
of patents, trademarks, developed technology, non-competes and
licenses, which are carried at amortized cost. We review our
definite-lived intangible assets whenever events or
circumstances indicate that the carrying amount of an asset may
not be recoverable. We assess recoverability by reference to
future cash flows from the products underlying these intangible
assets. If these estimates change in the future, we may be
required to record impairment charges for these assets.
Revenue Recognition: We recognize revenue when
the product has been shipped to the customer if there is
evidence that the customer has agreed to purchase the products,
delivery and performance have occurred, the price and terms of
sale are fixed and collection of the receivable is expected.
Less than five percent of our revenue is derived from consigned
inventory, for which we recognize revenue upon customer use and
receipt of proper purchase order
and/or
purchase requisition documentation. All amounts billed to
customers in a sales transaction related to shipping and
handling are classified as revenue. Our sales policy does not
allow sales returns.
Shipping and Handling: We record all amounts
billed to customers in a sales transaction related to shipping
and handling as net revenue. We record costs related to shipping
and handling in cost of revenue.
Research and Development: Research and
development costs are expensed as incurred.
Stock-Based Compensation: We recognize
stock-based compensation based on certain assumptions within the
Black-Scholes Model. These assumptions are used to determine an
estimated fair value of stock based payment awards on the date
of grant and require subjective judgment. Because employee stock
options have characteristics significantly different from those
of traded options, and because changes in the assumptions can
materially affect the fair value estimate, the existing models
may not provide a reliable single measure of the fair value of
the employee stock options. We assess the assumptions and
methodologies used to calculate the estimated fair value of
stock-based compensation on a regular basis. Circumstances may
change
35
SYNOVIS
LIFE TECHNOLOGIES, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
and additional data may become available over time, which could
result in changes to these assumptions and methodologies and
thereby materially impact our fair value determination.
Income Taxes: We account for income taxes
using the asset and liability method. The asset and liability
method provides that deferred tax assets and liabilities are
recorded based on the differences between the tax basis of
assets and liabilities and their carrying amounts for financial
reporting purposes (temporary differences). Deferred
tax assets are reduced by a valuation allowance, when, in the
opinion of management, it is more likely than not that some
portion or all of the deferred tax assets will not be realized.
We recognize the financial statement benefit of a tax position
only after determining that the relevant tax authority would
more likely than not sustain the position following an audit.
For tax positions meeting the more-likely-than-not threshold,
the amount recognized in the financial statements is the largest
benefit that has a greater than 50 percent likelihood of
being realized upon ultimate settlement with the relevant tax
authority.
Net Earnings (Loss) Per Share: Basic earnings
per share (EPS) is computed based on the weighted
average number of common shares outstanding, while diluted EPS
is computed based on the weighted average number of common
shares outstanding adjusted by the weighted average number of
additional shares that would have been outstanding had the
potential dilutive common shares been issued. Potential dilutive
shares of common stock include stock options and other
stock-based awards granted under the Companys stock-based
compensation plans, when their impact is not anti-dilutive. See
Note 11 for additional earnings per share information.
Reclassifications: Certain reclassifications
have been made to the fiscal 2008 and fiscal 2009 consolidated
financial statements to conform with the fiscal 2010
presentation. These reclassifications had no effect on net
income or earnings per share.
|
|
2.
|
Acquisition
of Business (in thousands):
|
On July 17, 2009, we, through our wholly-owned subsidiary
Ortho & Wound, completed the acquisition of
substantially all of the assets of Pegasus Biologics, Inc.
(Pegasus) from Comerica Bank (Comerica)
pursuant to a Foreclosure Sale Agreement with Comerica dated as
of July 2, 2009 (the Foreclosure Sale
Agreement). The acquisition resulted from a sealed bid
auction process after Pegasus effectively ceased operations when
attempts to raise additional operating capital were
unsuccessful. Pegasus, a privately held medical device company
based in Irvine, California, focused on the development of
advanced biological solutions for soft tissue repair.
We paid $12,100 in cash to Comerica for the assets transferred.
We purchased the assets on an as is, where
is basis and without recourse, subject to the
representations and warranties provided for in the Foreclosure
Sale Agreement.
Operating results for Ortho & Wound from
November 1, 2009 to October 31, 2010 are included in
the Consolidated Condensed Statements of Income and Cash Flows
for the fiscal year ended October 31, 2010. Operating
results for Ortho & Wound from July 17, 2009 to
October 31, 2009 are included in the Consolidated Condensed
Statement of Income for the fiscal year ended October 31,
2009. The assets acquired in the transaction are included in the
Companys Consolidated Condensed Balance Sheet as of
October 31, 2009.
We accounted for the acquisition of the assets of Pegasus under
the purchase method of accounting. Accordingly, the purchase
price was allocated to the tangible and intangible assets
acquired based on our determination of fair value at the
acquisition date, and are consolidated with those of the
Company. The purchase price allocation was based upon estimates
of the fair value of the assets acquired. Determination of fair
value required the use of significant assumptions and estimates,
including but not limited to, expected utilization of acquired
inventory, future expected cash flows and applicable discount
rates. We used the income approach to determine the fair value
of the acquired intangible assets.
36
SYNOVIS
LIFE TECHNOLOGIES, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The following provides further information on the purchase price
allocations:
Purchase Price
|
|
|
|
|
Cash payment
|
|
$
|
12,100
|
|
Acquisition related costs
|
|
|
219
|
|
|
|
|
|
|
Total consideration
|
|
$
|
12,319
|
|
|
|
|
|
|
Purchase Price Allocation
|
|
|
|
|
Accounts receivable
|
|
$
|
50
|
|
Inventory
|
|
|
2,053
|
|
Other current assets
|
|
|
42
|
|
Property and equipment
|
|
|
674
|
|
Identifiable intangible assets
|
|
|
|
|
Developed technology
|
|
|
6,000
|
|
Acquired in-process research and development
|
|
|
3,500
|
|
|
|
|
|
|
Assets acquired
|
|
$
|
12,319
|
|
|
|
|
|
|
In accordance with GAAP, we expensed the acquired in-process
research and development costs of $3,500 in fiscal 2009. This
expense was recorded as other operating expense in
the Consolidated Statement of Income for fiscal 2009. We
assigned an eleven year weighted average amortization period to
the identifiable developed technology assets. As we assigned the
entire purchase price to tangible and identifiable intangible
assets, none of the preliminary purchase price was allocated to
goodwill.
Pro Forma Results of Operations:
The following unaudited pro forma financial information presents
a summary of our consolidated results of operations as if the
acquisition of the assets of Pegasus had occurred at the
beginning of the earliest period presented. The unaudited pro
forma results presented below assume the in-process research and
development expense of $3,500 occurred as of November 1,
2007. Annual amortization expense of $545 related to acquired
developed technology is reflected on a pro rata basis in each of
the periods presented. The historical consolidated financial
information has been adjusted to give effect to pro forma events
that are directly attributable to the acquisition and are
factually supportable. The unaudited pro forma condensed
consolidated financial information is presented for
informational purposes only. The pro forma information is not
necessarily indicative of what the financial position or results
of operations actually would have been had the acquisition been
completed at the dates indicated. In addition, the unaudited pro
forma condensed consolidated financial information does not
purport to project our future financial position or operating
results after completion of the acquisition.
The following provides unaudited pro forma financial information
for the fiscal years ended October 31, 2009 and 2008,
assuming we consummated the purchase of the assets from Pegasus
as of November 1, 2007:
|
|
|
|
|
|
|
|
|
|
|
Fiscal Year
|
|
|
Fiscal Year
|
|
|
|
Ended
|
|
|
Ended
|
|
|
|
October 31,
|
|
|
October 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
Net revenue
|
|
$
|
61,853
|
|
|
$
|
58,924
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
(1,886
|
)
|
|
$
|
(135
|
)
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share basic
|
|
$
|
(0.16
|
)
|
|
$
|
(0.01
|
)
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share diluted
|
|
$
|
(0.16
|
)
|
|
$
|
(0.01
|
)
|
|
|
|
|
|
|
|
|
|
37
SYNOVIS
LIFE TECHNOLOGIES, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
3.
|
Discontinued
Operations (in thousands):
|
On January 31, 2008, we sold substantially all of the
assets of Synovis interventional business to Heraeus
Vadnais, Inc. and its related entities (Heraeus),
pursuant to an Asset Purchase Agreement dated January 8,
2008. Our interventional business developed and manufactured
metal and polymer components and assemblies used in or with
implantable or minimally invasive devices for cardiac rhythm
management, neurostimulation, vascular and other procedures, and
had facilities located in Lino Lakes, Minnesota and Dorado,
Puerto Rico. The decision to sell the interventional business
resulted from our determination to focus our attention and
resources on opportunities in our surgical markets.
The primary terms of the sale included the following:
|
|
|
|
|
Heraeus paid Synovis $30,440 in cash (the Purchase
Price) for substantially all of the assets (including
receivables, inventory, fixed assets and intellectual property)
and assumed certain operating liabilities of the interventional
business. This was comprised of an initial payment of $29,500 on
January 31, 2008, plus a working capital adjustment payment
of $940, which we received during our second quarter of fiscal
2008.
|
|
|
|
$2,950 of the Purchase Price was placed in escrow until
July 31, 2009 to cover certain post-closing covenants and
potential indemnification obligations. The escrow amount was
included in our net gain from the sale, and recorded as
restricted cash on our balance sheet as of October 31, 2008.
|
We recorded a pretax gain of $11,423 and a provision for income
taxes of $6,083, resulting in a net gain on sale of $5,340. The
net gain was computed as follows:
Carrying values of net assets transferred to Heraeus:
|
|
|
|
|
Accounts receivable
|
|
$
|
3,186
|
|
Inventories
|
|
|
4,843
|
|
Other assets
|
|
|
208
|
|
Property, plant and equipment
|
|
|
6,381
|
|
Other intangible assets
|
|
|
4,269
|
|
Accounts payable and accrued liabilities
|
|
|
(479
|
)
|
|
|
|
|
|
Total
|
|
$
|
18,408
|
|
|
|
|
|
|
Cash proceeds received from Heraeus, including escrow
|
|
$
|
30,440
|
|
Net assets sold
|
|
|
(18,408
|
)
|
Transaction costs
|
|
|
(609
|
)
|
|
|
|
|
|
Pre-tax gain on sale of discontinued operations
|
|
|
11,423
|
|
Tax provision for gain on sale of discontinued operations
|
|
|
6,083
|
|
|
|
|
|
|
Net gain on sale of discontinued operations
|
|
$
|
5,340
|
|
|
|
|
|
|
38
SYNOVIS
LIFE TECHNOLOGIES, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Operating results related to the divested operations for fiscal
2008 have been reclassified and are presented in our
consolidated Statement of Income as discontinued operations, as
summarized below:
|
|
|
|
|
|
|
For the Fiscal Year Ended
|
|
|
|
October 31,
|
|
|
|
2008
|
|
|
Net revenue
|
|
$
|
7,907
|
|
Cost of revenue
|
|
|
6,361
|
|
|
|
|
|
|
Gross margin
|
|
|
1,546
|
|
Operating expenses
|
|
|
1,576
|
|
|
|
|
|
|
Operating loss from discontinued operations
|
|
|
(30
|
)
|
Benefit from income taxes
|
|
|
(10
|
)
|
|
|
|
|
|
Net loss from discontinued operations
|
|
$
|
(20
|
)
|
|
|
|
|
|
|
|
4.
|
Supplemental
Financial Statement Information (in thousands):
|
As a developer, manufacturer and seller of medical devices, we
have a single reporting segment.
|
|
|
|
|
|
|
|
|
|
|
As of October 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
Accounts receivable, net:
|
|
|
|
|
|
|
|
|
Trade receivables
|
|
$
|
9,104
|
|
|
$
|
7,269
|
|
Allowance for doubtful accounts
|
|
|
(403
|
)
|
|
|
(344
|
)
|
|
|
|
|
|
|
|
|
|
|
|
$
|
8,701
|
|
|
$
|
6,925
|
|
|
|
|
|
|
|
|
|
|
Inventories:
|
|
|
|
|
|
|
|
|
Finished goods
|
|
$
|
4,524
|
|
|
$
|
2,793
|
|
Work in process
|
|
|
3,533
|
|
|
|
3,573
|
|
Raw materials
|
|
|
1,376
|
|
|
|
1,358
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
9,433
|
|
|
$
|
7,724
|
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net:
|
|
|
|
|
|
|
|
|
Furniture, fixtures, and computer equipment
|
|
$
|
3,035
|
|
|
$
|
3,180
|
|
Manufacturing equipment
|
|
|
5,701
|
|
|
|
5,071
|
|
Leasehold improvements
|
|
|
3,162
|
|
|
|
3,110
|
|
Equipment in process
|
|
|
534
|
|
|
|
697
|
|
Accumulated depreciation and amortization
|
|
|
(9,031
|
)
|
|
|
(8,339
|
)
|
|
|
|
|
|
|
|
|
|
|
|
$
|
3,401
|
|
|
$
|
3,719
|
|
|
|
|
|
|
|
|
|
|
Accrued expenses:
|
|
|
|
|
|
|
|
|
Payroll, employee benefits and related taxes
|
|
$
|
4,191
|
|
|
$
|
3,081
|
|
Accrued income taxes
|
|
|
628
|
|
|
|
1,128
|
|
Accrued stock repurchases
|
|
|
75
|
|
|
|
198
|
|
Other accrued expenses
|
|
|
1,477
|
|
|
|
1,340
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
6,371
|
|
|
$
|
5,747
|
|
|
|
|
|
|
|
|
|
|
Supplemental Cash Flow Information: Our income
tax payments totaled $3,054, $850 and $8,599 for the years ended
October 31, 2010, 2009 and 2008, respectively. Our income
tax refunds received totaled $4, $118 and $95 for the years
ended October 31, 2010, 2009 and 2008, respectively.
39
SYNOVIS
LIFE TECHNOLOGIES, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The following table summarizes our amortizable intangible assets
as of:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
October 31, 2010
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
Gross
|
|
|
|
|
|
Average
|
|
|
|
Carrying
|
|
|
Accumulated
|
|
|
Amortization
|
|
|
|
Amount
|
|
|
Amortization
|
|
|
Period
|
|
|
Patents and trademarks
|
|
$
|
1,310
|
|
|
$
|
649
|
|
|
|
13
|
.7 years
|
Developed technology
|
|
|
7,418
|
|
|
|
1,993
|
|
|
|
10
|
.8 years
|
Non-competes and other
|
|
|
634
|
|
|
|
628
|
|
|
|
5
|
.7 years
|
Licenses
|
|
|
100
|
|
|
|
10
|
|
|
|
11
|
.0 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
9,462
|
|
|
$
|
3,280
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
October 31, 2009
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
Gross
|
|
|
|
|
|
Average
|
|
|
|
Carrying
|
|
|
Accumulated
|
|
|
Amortization
|
|
|
|
Amount
|
|
|
Amortization
|
|
|
Period
|
|
|
Patents and trademarks
|
|
$
|
1,187
|
|
|
$
|
600
|
|
|
|
13
|
.9 years
|
Developed technology
|
|
|
7,418
|
|
|
|
1,283
|
|
|
|
10
|
.8 years
|
Non-competes and other
|
|
|
634
|
|
|
|
612
|
|
|
|
5
|
.7 years
|
Licenses
|
|
|
100
|
|
|
|
3
|
|
|
|
11
|
.0 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
9,339
|
|
|
$
|
2,498
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In fiscal 2009, we recorded $6,000 in developed technology
related to the acquisition of the assets of Pegasus. Subsequent
to the acquisition, we paid cash consideration of $100 for
license rights related to acquired product manufacturing
processes.
In fiscal 2009, we recorded an impairment charge of $600 as an
other operating expense related to identifiable intangible
assets related to our fiscal 2007 acquisition of the
4Closuretm
Surgical Fascia Closure System (4Closure) following
an impairment analysis. A discounted cash flows impairment
analysis was performed as a result of a delay in the expected
third quarter of fiscal 2009 re-launch and re-brand of the
product, combined with actual revenues since acquisition not
meeting expectations.
Amortization expense for the intangible assets listed above was
$782, $539 and $437 in fiscal 2010, 2009 and 2008, respectively.
Our estimated amortization expense for each of the next five
years is expected to be approximately $800 per year based on the
current amortizable intangible assets owned by the Company.
|
|
5.
|
Supplemental
Net Revenue Information (in thousands):
|
The following table summarizes net revenues by product line for
the fiscal years ended October 31:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Revenues by Product Line:
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Veritas
|
|
$
|
14,368
|
|
|
$
|
8,757
|
|
|
$
|
4,468
|
|
Peri-Strips
|
|
|
19,414
|
|
|
|
19,384
|
|
|
|
17,653
|
|
Tissue-Guard
|
|
|
16,550
|
|
|
|
15,806
|
|
|
|
14,477
|
|
Microsurgery
|
|
|
11,020
|
|
|
|
8,668
|
|
|
|
7,749
|
|
Orthopedic and Wound
|
|
|
1,878
|
|
|
|
65
|
|
|
|
|
|
Surgical Tools and Other
|
|
|
5,335
|
|
|
|
5,531
|
|
|
|
5,453
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
68,565
|
|
|
$
|
58,211
|
|
|
$
|
49,800
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
40
SYNOVIS
LIFE TECHNOLOGIES, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Substantially all of our international net revenues are
negotiated, invoiced and paid in U.S. dollars. The
following table summarizes net revenues by geographic area for
the years ended October 31:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Revenues by Geographic Area:
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
United States
|
|
$
|
57,700
|
|
|
$
|
49,290
|
|
|
$
|
42,190
|
|
Europe
|
|
|
7,652
|
|
|
|
6,094
|
|
|
|
5,346
|
|
Asia and Pacific region
|
|
|
1,325
|
|
|
|
963
|
|
|
|
1,019
|
|
Canada
|
|
|
874
|
|
|
|
817
|
|
|
|
699
|
|
Other
|
|
|
1,014
|
|
|
|
1,047
|
|
|
|
546
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
68,565
|
|
|
$
|
58,211
|
|
|
$
|
49,800
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6.
|
Investments
(in thousands):
|
The following table summarizes our cash, cash equivalents and
investments at October 31, 2010 and 2009:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
October 31, 2010
|
|
|
|
Amortized
|
|
|
Unrealized
|
|
|
Estimated
|
|
|
|
Cost
|
|
|
Gain (Loss)
|
|
|
Fair Value
|
|
|
Cash
|
|
$
|
7,416
|
|
|
$
|
|
|
|
$
|
7,416
|
|
Money Market Funds
|
|
|
5,535
|
|
|
|
|
|
|
|
5,535
|
|
Municipal Bonds
|
|
|
30,864
|
|
|
|
(8
|
)
|
|
|
30,856
|
|
Commercial Paper
|
|
|
1,994
|
|
|
|
3
|
|
|
|
1,997
|
|
Corporate Bonds
|
|
|
15,089
|
|
|
|
30
|
|
|
|
15,119
|
|
Treasuries and Agencies
|
|
|
1,000
|
|
|
|
1
|
|
|
|
1,001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
61,898
|
|
|
$
|
26
|
|
|
$
|
61,924
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
12,951
|
|
|
|
|
|
|
$
|
12,951
|
|
Short-term investments
|
|
|
41,079
|
|
|
|
40
|
|
|
|
41,119
|
|
Long-term investments
|
|
|
7,868
|
|
|
|
(14
|
)
|
|
|
7,854
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
61,898
|
|
|
$
|
26
|
|
|
$
|
61,924
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
October 31, 2009
|
|
|
|
Amortized
|
|
|
Unrealized
|
|
|
Estimated
|
|
|
|
Cost
|
|
|
Gain
|
|
|
Fair Value
|
|
|
Cash
|
|
$
|
1,752
|
|
|
$
|
|
|
|
$
|
1,752
|
|
Money Market Funds
|
|
|
14,111
|
|
|
|
|
|
|
|
14,111
|
|
Municipal Bonds
|
|
|
44,794
|
|
|
|
92
|
|
|
|
44,886
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
60,657
|
|
|
$
|
92
|
|
|
$
|
60,749
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
15,863
|
|
|
|
|
|
|
$
|
15,863
|
|
Short-term investments
|
|
|
38,879
|
|
|
|
81
|
|
|
|
38,960
|
|
Long-term investments
|
|
|
5,915
|
|
|
|
11
|
|
|
|
5,926
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
60,657
|
|
|
$
|
92
|
|
|
$
|
60,749
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At October 31, 2010, our long-term investments mature in
fiscal 2012.
In fiscal 2009, we sold our auction rate securities
(ARS), which had a par value of $9,000, for $7,650,
realizing a loss on sale of $1,350.
41
SYNOVIS
LIFE TECHNOLOGIES, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
7.
|
Fair
Value Measurements (in thousands):
|
The following table provides our investment assets carried at
fair value measured on a recurring basis as of October 31,
2010 and 2009:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurements at October 31, 2010 Using
|
|
|
|
|
|
|
|
|
|
Significant Other
|
|
|
|
|
|
|
Total Carrying
|
|
|
Quoted Price in
|
|
|
Observable
|
|
|
Significant
|
|
|
|
Value at
|
|
|
Active Markets
|
|
|
Inputs
|
|
|
Unobservable Inputs
|
|
|
|
October 31, 2010
|
|
|
(Level 1)
|
|
|
(Level 2)
|
|
|
(Level 3)
|
|
|
Investments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Municipal Bonds
|
|
|
30,856
|
|
|
|
|
|
|
|
30,856
|
|
|
|
|
|
Commercial Paper
|
|
|
1,997
|
|
|
|
|
|
|
|
1,997
|
|
|
|
|
|
Corporate Bonds
|
|
|
15,119
|
|
|
|
|
|
|
|
15,119
|
|
|
|
|
|
Treasuries and Agencies
|
|
|
1,001
|
|
|
|
|
|
|
|
1,001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total investments
|
|
$
|
48,973
|
|
|
$
|
|
|
|
$
|
48,973
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurements at October 31, 2009 Using
|
|
|
|
|
|
|
|
|
|
Significant Other
|
|
|
|
|
|
|
Total Carrying
|
|
|
Quoted Price in
|
|
|
Observable
|
|
|
Significant
|
|
|
|
Value At
|
|
|
Active Markets
|
|
|
Inputs
|
|
|
Unobservable Inputs
|
|
|
|
October 31, 2009
|
|
|
(Level 1)
|
|
|
(Level 2)
|
|
|
(Level 3)
|
|
|
Investments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Municipal Bonds
|
|
|
44,886
|
|
|
|
|
|
|
|
44,886
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total investments
|
|
$
|
44,886
|
|
|
$
|
|
|
|
$
|
44,886
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
We utilize a pricing service to estimate fair value measurements
for our short- and long-term investments. The pricing service
utilizes market quotations for fixed maturity securities that
have quoted prices in active markets. Since fixed maturities
other than U.S. Treasury securities generally do not trade
on a daily basis, the pricing service prepares estimates of fair
value measurements for these securities using its proprietary
pricing applications which include available relevant market
information, benchmark curves, benchmarking of like securities,
sector groupings and matrix pricing.
The fair value estimates provided by the pricing service for our
investments are based on observable market information rather
than market quotes. Accordingly, the estimates of fair value for
our investments were determined based on Level 2 inputs at
October 31, 2010 and 2009, respectively.
|
|
8.
|
Income
Taxes (in thousands):
|
The components of our provision for (benefit from) income taxes
are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Fiscal Years Ended
|
|
|
|
October 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Current:
|
|
|
|
|
|
|
|
|
|
|
|
|
Federal
|
|
$
|
2,218
|
|
|
$
|
2,752
|
|
|
$
|
2,509
|
|
State
|
|
|
642
|
|
|
|
320
|
|
|
|
96
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,860
|
|
|
|
3,072
|
|
|
|
2,605
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred:
|
|
|
|
|
|
|
|
|
|
|
|
|
Federal
|
|
|
(108
|
)
|
|
|
(2,016
|
)
|
|
|
351
|
|
State
|
|
|
(9
|
)
|
|
|
(190
|
)
|
|
|
150
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(117
|
)
|
|
|
(2,206
|
)
|
|
|
501
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
2,743
|
|
|
$
|
866
|
|
|
$
|
3,106
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
42
SYNOVIS
LIFE TECHNOLOGIES, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Reconciliation of effective income tax rate:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Fiscal Years Ended
|
|
|
|
October 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Income before income taxes
|
|
$
|
7,619
|
|
|
$
|
3,572
|
|
|
$
|
9,271
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Statutory federal rate
|
|
|
2,591
|
|
|
|
1,215
|
|
|
|
3,245
|
|
State taxes, net of federal benefit
|
|
|
410
|
|
|
|
112
|
|
|
|
228
|
|
Tax exempt interest
|
|
|
(54
|
)
|
|
|
(169
|
)
|
|
|
(147
|
)
|
Other permanent differences
|
|
|
(109
|
)
|
|
|
(117
|
)
|
|
|
(45
|
)
|
Research and development credits
|
|
|
(95
|
)
|
|
|
(175
|
)
|
|
|
(175
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Provision for income taxes
|
|
$
|
2,743
|
|
|
$
|
866
|
|
|
$
|
3,106
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Components of deferred income tax assets and liabilities:
|
|
|
|
|
|
|
|
|
|
|
As of October 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
Inventory
|
|
$
|
316
|
|
|
$
|
273
|
|
Other, net
|
|
|
51
|
|
|
|
94
|
|
|
|
|
|
|
|
|
|
|
Net current deferred income tax assets
|
|
|
367
|
|
|
|
367
|
|
Depreciation
|
|
|
(26
|
)
|
|
|
253
|
|
Stock-based compensation expense
|
|
|
768
|
|
|
|
360
|
|
Intangible asset amortization
|
|
|
1,397
|
|
|
|
1,382
|
|
Other, net
|
|
|
|
|
|
|
27
|
|
|
|
|
|
|
|
|
|
|
Net long-term deferred income tax assets
|
|
|
2,139
|
|
|
|
2,022
|
|
|
|
|
|
|
|
|
|
|
Net deferred income tax assets
|
|
$
|
2,506
|
|
|
$
|
2,389
|
|
|
|
|
|
|
|
|
|
|
A net income tax payable of $628 was recorded at
October 31, 2010, as compared to $1,128 at October 31,
2009. A tax benefit of $296, $203 and $441 related to the
exercise of stock options was recorded to additional paid-in
capital in fiscal 2010, 2009 and 2008, respectively.
Significant judgment is required in evaluating our uncertain tax
positions. During the ordinary course of business, there are
many transactions and calculations for which the ultimate tax
determination is uncertain. We establish reserves for
tax-related uncertainties based on estimates of whether, and the
extent to which, additional taxes may be due. These reserves are
established when we believe that certain positions might be
challenged despite our belief that our tax return positions are
fully supportable. We adjust these reserves in light of changing
facts and circumstances, such as the outcome of a tax audit or
changes in the tax law. The provision for income taxes includes
the impact of reserve provisions and changes to reserves that
are considered appropriate.
We are subject to income taxes in the U.S. Federal
jurisdiction, Minnesota and various states. Tax regulations
within each jurisdiction are subject to the interpretation of
the related tax laws and regulations and require significant
judgment to apply. With few exceptions, we are no longer subject
to U.S. federal, state or local income tax examinations by
tax authorities for the fiscal years ended before
October 31, 2007. We were recently under examination for
the years ended October 31, 2008 and 2007 by the Internal
Revenue Service. The examination concluded in February 2010 and
did not have a significant impact on the recognition of
unrecognized tax benefits.
43
SYNOVIS
LIFE TECHNOLOGIES, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Uncertain tax positions:
At October 31, 2010, we had unrecognized tax benefits of
$393. If recognized, these benefits would favorably impact the
effective tax rate. A reconciliation of the beginning and ending
amount of unrecognized tax benefits is as follows:
|
|
|
|
|
|
|
|
|
For the Fiscal Years Ended October 31,
|
|
2010
|
|
|
2009
|
|
|
Beginning balance
|
|
$
|
435
|
|
|
$
|
387
|
|
Increases for current period tax positions
|
|
|
185
|
|
|
|
48
|
|
Decreases for lapses in applicable statute of limitations
|
|
|
(227
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ending balance
|
|
$
|
393
|
|
|
$
|
435
|
|
|
|
|
|
|
|
|
|
|
Our policy is to include interest and penalties related to our
tax contingencies in income tax expense.
|
|
9.
|
Commitments
and Contingencies (in thousands):
|
Operating Leases: We are committed under
non-cancelable operating leases for our office and production
facilities. At October 31, 2010, the remaining terms on the
leases range from one to four years. In addition to base rent
charges, we also pay apportioned real estate taxes and common
costs on our St. Paul, MN and Irvine, CA leased facilities. We
have an option to renew our St. Paul, MN lease prior to
December 31, 2013 for an additional three or five years at
fair market value. Total facilities rent expense, including real
estate taxes and common costs, was $1,464, $1,200 and $1,038 for
the fiscal years ended October 31, 2010, 2009 and 2008,
respectively.
As of October 31, 2010, future minimum lease payments,
excluding real estate taxes and common costs, due under existing
non-cancelable operating leases are as follows:
|
|
|
|
|
Fiscal Years Ended October 31,
|
|
|
|
|
2011
|
|
$
|
1,020
|
|
2012
|
|
|
982
|
|
2013
|
|
|
738
|
|
2014
|
|
|
121
|
|
|
|
|
|
|
|
|
$
|
2,861
|
|
|
|
|
|
|
Royalties: We incurred royalty expense,
primarily related to revenue from Peri-Strips and our
Ortho & Wound products, of approximately $827, $753
and $696 for the years ended October 31, 2010, 2009 and
2008, respectively, which is included in cost of revenue. Fiscal
2010 royalty expense included minimum royalties we are obligated
to pay on sales of our Ortho & Wound products, which
totaled $101 for the year.
|
|
10.
|
Shareholders
Equity (in thousands except share and per share data):
|
Authorized Shares: Our authorized capital
stock consists of 20,000,000 shares of common stock and
5,000,000 shares of undesignated preferred stock.
Shareholder Rights Agreement: On June 1,
2006, our board of directors declared a dividend distribution of
one common stock purchase right for each outstanding share of
our common stock, payable to shareholders of record at the close
of business on June 11, 2006. The description and terms of
the rights are set forth in a Rights Agreement (the Rights
Agreement), dated as of June 1, 2006, between us and
American Stock Transfer & Trust Company, as
Rights Agent. The Rights Agreement was approved by the
shareholders at our 2007 Annual Meeting of Shareholders.
44
SYNOVIS
LIFE TECHNOLOGIES, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Upon certain acquisition events set forth in the Rights
Agreement, each holder of a right other than certain
acquiring persons, will have the right to receive
upon exercise for a purchase price equal to ten times the
purchase price of the right, shares of our common stock (or in
certain circumstances, cash, property or other securities)
having a market value equal to 20 times the purchase price.
Stock-Based Compensation: Our current
stock-based compensation plans consist of our 2006 Stock
Incentive Plan, as amended (the 2006 Plan), and an
Employee Stock Purchase Plan (ESPP). Under the 2006
Plan, we are authorized to issue up to 1,500,000 shares of
our common stock, plus certain shares becoming available under
our prior 1995 Stock Incentive Plan or issued or assumed by us
in certain merger or acquisition transactions, pursuant to
incentive awards granted under the plan. At October 31,
2010, 346,686 shares remained available for grant under the
2006 Plan. Under the ESPP, we are authorized to sell and issue
up to 400,000 shares of our common stock to our employees.
At October 31, 2010, a total of 101,521 shares
remained available for issuance under the ESPP.
The 2006 Plan was approved by our shareholders in February 2006,
and an increase in the number of shares available for issuance
was approved by our shareholders in March 2009. The 2006 Plan
permits us to grant incentive stock options, non-qualified stock
options and other share-based awards to eligible recipients for
up to 1,500,000 shares of our common stock, plus the number
of shares or awards outstanding under our prior 1995 Stock
Incentive Plan as of its expiration which are subsequently
cancelled or forfeited. The grant price of an option under the
2006 Plan may not be less than the fair market value of the
common stock subject to the option as of the grant date. The
term of any options granted under the 2006 Plan may not exceed
seven years from the date of grant. As of October 31, 2010,
1,452,938 stock options have been granted under the 2006 Plan.
We recognized compensation expense for stock-based compensation
awards on a straight-line basis over the requisite service
period of all stock-based compensation awards granted to, but
not yet vested. Total stock-based compensation expense included
in our Statements of Income for the years ended October 31,
2010, 2009 and 2008 was $1,455 ($1,013, net of tax), $937 ($804,
net of tax) and $509 ($405, net of tax), respectively.
We estimated the fair values of our stock options using the
Black-Scholes option-pricing model. The Black-Scholes option
valuation weighted average assumptions used in the valuation of
stock options for the fiscal years ended October 31, 2010,
2009 and 2008 were as follows:
|
|
|
|
|
|
|
|
|
2010
|
|
2009
|
|
2008
|
|
Risk-free rate(1)
|
|
1.9%
|
|
1.1%
|
|
2.7%
|
Expected dividend yield
|
|
None
|
|
None
|
|
None
|
Expected stock volatility(2)
|
|
54%
|
|
50%
|
|
46%
|
Expected life of stock options(3)
|
|
4.0 years
|
|
3.0 years
|
|
2.8 years
|
Fair value per option
|
|
$5.11 $6.93
|
|
$4.30 $7.41
|
|
$5.21 $6.39
|
Forfeiture rate
|
|
10%
|
|
8%
|
|
8%
|
|
|
|
(1) |
|
Based on the U.S Treasury Strip interest rates whose term is
consistent with the expected life of the stock options. |
|
(2) |
|
Expected stock price volatility is based on our historical
volatility over a period generally consistent with the expected
term of our stock options. |
|
(3) |
|
Expected life of stock options is estimated based on historical
experience. |
As of October 31, 2010, there was $2,444 of unrecognized
compensation expense related to unvested stock options that is
expected to be recognized over a weighted average period of
approximately two years.
45
SYNOVIS
LIFE TECHNOLOGIES, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Stock Options: The exercise price of each
stock option equals 100% of the market price of our common stock
on the date of grant and has a maximum term ranging from 7 to
10 years. Stock options granted to non-employee directors
and employees generally vest ratably over two or three years. A
summary of the status of our stock options for the years ended
October 31 is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
Average
|
|
|
|
|
|
Average
|
|
|
|
|
|
Average
|
|
|
|
|
|
|
Exercise
|
|
|
|
|
|
Exercise
|
|
|
|
|
|
Exercise
|
|
|
|
Shares
|
|
|
Price
|
|
|
Shares
|
|
|
Price
|
|
|
Shares
|
|
|
Price
|
|
|
Outstanding at beginning of year
|
|
|
736,376
|
|
|
$
|
10.48
|
|
|
|
689,761
|
|
|
$
|
9.32
|
|
|
|
906,538
|
|
|
$
|
8.84
|
|
Granted
|
|
|
728,116
|
|
|
|
12.24
|
|
|
|
161,880
|
|
|
|
15.24
|
|
|
|
28,682
|
|
|
|
18.75
|
|
Exercised
|
|
|
(204,807
|
)
|
|
|
9.01
|
|
|
|
(89,376
|
)
|
|
|
8.12
|
|
|
|
(158,635
|
)
|
|
|
8.50
|
|
Cancelled
|
|
|
(72,707
|
)
|
|
|
12.91
|
|
|
|
(25,889
|
)
|
|
|
17.39
|
|
|
|
(86,824
|
)
|
|
|
8.93
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at end of year
|
|
|
1,186,978
|
|
|
$
|
11.67
|
|
|
|
736,376
|
|
|
$
|
10.48
|
|
|
|
689,761
|
|
|
$
|
9.32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options exercisable at end of year
|
|
|
722,211
|
|
|
$
|
11.23
|
|
|
|
661,201
|
|
|
$
|
9.95
|
|
|
|
513,625
|
|
|
$
|
9.56
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The total intrinsic value of options exercised during the fiscal
year ended October 31, 2010, 2009 and 2008 was $4,140, $737
and $1,631, respectively. The aggregate intrinsic value of
options outstanding and exercisable as of October 31, 2010
was $2,883. The weighted-average remaining contractual term of
options outstanding and exercisable as of October 31, 2010
was 2.6 years.
The following table summarizes information about stock options
outstanding at October 31, 2010:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
|
|
|
Average
|
|
|
|
|
|
Average
|
|
|
|
|
|
|
Weighted
|
|
|
Remaining
|
|
|
|
|
|
Exercise
|
|
|
|
Number of
|
|
|
Average
|
|
|
Contractual
|
|
|
Number of
|
|
|
Price of
|
|
|
|
Options
|
|
|
Exercise
|
|
|
Life
|
|
|
Options
|
|
|
Exercisable
|
|
Range of Prices
|
|
Outstanding
|
|
|
Price
|
|
|
(Years)
|
|
|
Exercisable
|
|
|
Options
|
|
|
$ 7.50 $11.81
|
|
|
325,600
|
|
|
$
|
8.15
|
|
|
|
1.59
|
|
|
|
323,600
|
|
|
$
|
8.13
|
|
12.00 12.00
|
|
|
604,900
|
|
|
|
12.00
|
|
|
|
4.96
|
|
|
|
201,633
|
|
|
|
12.00
|
|
12.16 21.45
|
|
|
256,478
|
|
|
|
15.35
|
|
|
|
3.47
|
|
|
|
196,978
|
|
|
|
15.54
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 7.50 $21.45
|
|
|
1,186,978
|
|
|
$
|
11.67
|
|
|
|
3.71
|
|
|
|
722,211
|
|
|
$
|
11.23
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employee Stock Purchase Plan: We sponsor an
ESPP under which 400,000 shares of common stock were
reserved for future issuance. The ESPP was established to enable
our employees to invest in our common stock through payroll
deductions. Shares are available to employees to purchase shares
of stock at a price equal to 95% of the fair market value of the
stock on the last day of each offering period. There were
10,809, 7,065 and 4,900 shares purchased through the ESPP
in fiscal 2010, 2009 and 2008, respectively.
Repurchase of Common Shares: On May 28,
2008, we announced that its Board of Directors had authorized
the repurchase up to 1,000,000 shares of our common stock.
This program was completed on January 9, 2009. The share
repurchase was funded using our existing cash balances and
occurred in the open market in accordance with SEC regulations.
The timing and extent to which we bought back shares depended
upon market conditions and other corporate considerations.
From inception of the program on May 28, 2008 through its
completion on January 9, 2009, we used $16,675 to
repurchase 1,000,000 shares at an average price of $16.68
per share. The following table presents
46
SYNOVIS
LIFE TECHNOLOGIES, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
the total number of shares repurchased from May 28, 2008
through January 9, 2009, the average price paid per share
and the number of shares that were purchased.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Number
|
|
|
Maximum
|
|
|
|
|
|
|
|
|
|
of Shares
|
|
|
Number
|
|
|
|
|
|
|
|
|
|
Purchased
|
|
|
of Shares That
|
|
|
|
|
|
|
|
|
|
as Part of
|
|
|
May Yet Be
|
|
|
|
Total
|
|
|
Average
|
|
|
Publicly
|
|
|
Purchased
|
|
|
|
Number
|
|
|
Price
|
|
|
Announced
|
|
|
Under the
|
|
|
|
of Shares
|
|
|
Paid per
|
|
|
Plan or
|
|
|
Plan
|
|
Period
|
|
Purchased
|
|
|
Share
|
|
|
Program
|
|
|
or Program
|
|
|
May 1, 2008 May 31, 2008
|
|
|
|
|
|
$
|
|
|
|
|
|
|
|
|
1,000,000
|
|
June 1, 2008 June 30, 2008
|
|
|
87,585
|
|
|
|
17.82
|
|
|
|
87,585
|
|
|
|
912,415
|
|
October 1, 2008 October 31, 2008
|
|
|
416,582
|
|
|
|
16.77
|
|
|
|
504,167
|
|
|
|
495,833
|
|
November 1, 2008 November 30, 2008
|
|
|
145,833
|
|
|
|
16.67
|
|
|
|
650,000
|
|
|
|
350,000
|
|
December 1, 2008 December 31, 2008
|
|
|
294,801
|
|
|
|
16.02
|
|
|
|
944,801
|
|
|
|
55,199
|
|
January 1, 2009 January 31, 2009
|
|
|
55,199
|
|
|
|
17.61
|
|
|
|
1,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
1,000,000
|
|
|
$
|
16.68
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
On September 29, 2009, we announced that our Board of
Directors had authorized the repurchase of up to
500,000 shares of our common stock. On March 4, 2010,
the Board of Directors increased the number of shares we are
authorized to repurchase by an incremental 1,000,000 shares
of our common stock, for a total of 1,500,000 shares to be
repurchased. The share repurchase is funded using our existing
cash balances and may occur either in the open market or through
private transactions from time to time, in accordance with SEC
regulations. The timing and extent to which we may buy back
shares depends upon market conditions and other corporate
considerations. The repurchase plan does not have an expiration
date.
From inception of the program on September 29, 2009 through
October 31, 2010, we used $7,994 to repurchase
606,240 shares at an average price of $13.19 per share. The
following table presents the total number of shares repurchased
from September 29, 2009 through October 31, 2010, the
average price paid per share and the number of shares that were
purchased and the maximum number of shares that may yet be
purchased at October 31, 2010, pursuant to our stock
repurchase program:
47
SYNOVIS
LIFE TECHNOLOGIES, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Number
|
|
|
Maximum
|
|
|
|
|
|
|
|
|
|
of Shares
|
|
|
Number of
|
|
|
|
|
|
|
|
|
|
Purchased
|
|
|
Shares That
|
|
|
|
|
|
|
|
|
|
as Part of
|
|
|
May Yet Be
|
|
|
|
Total
|
|
|
Average
|
|
|
Publicly
|
|
|
Purchased
|
|
|
|
Number
|
|
|
Price
|
|
|
Announced
|
|
|
Under the
|
|
|
|
of Shares
|
|
|
Paid per
|
|
|
Plan or
|
|
|
Plan
|
|
Period
|
|
Purchased
|
|
|
Share
|
|
|
Program
|
|
|
or Program
|
|
|
September 29, 2009 September 30, 2009
|
|
|
43,968
|
|
|
$
|
13.75
|
|
|
|
43,968
|
|
|
|
456,032
|
|
October 1, 2009 October 31, 2009
|
|
|
176,436
|
|
|
|
12.97
|
|
|
|
220,404
|
|
|
|
279,596
|
|
November 1, 2009 November 30, 2009
|
|
|
213,377
|
|
|
|
11.96
|
|
|
|
433,781
|
|
|
|
66,219
|
|
December 1, 2009 December 31, 2009
|
|
|
|
|
|
|
|
|
|
|
433,781
|
|
|
|
66,219
|
|
January 1, 2010 January 31, 2010
|
|
|
|
|
|
|
|
|
|
|
433,781
|
|
|
|
66,219
|
|
February 1, 2010 February 28, 2010
|
|
|
|
|
|
|
|
|
|
|
433,781
|
|
|
|
66,219
|
|
March 1, 2010 March 31, 2010
|
|
|
|
|
|
|
|
|
|
|
433,781
|
|
|
|
1,066,219
|
|
April 1, 2010 April 30, 2010
|
|
|
|
|
|
|
|
|
|
|
433,781
|
|
|
|
1,066,219
|
|
May 1, 2010 May 31, 2010
|
|
|
|
|
|
|
|
|
|
|
433,781
|
|
|
|
1,066,219
|
|
June 1, 2010 June 30, 2010
|
|
|
|
|
|
|
|
|
|
|
433,781
|
|
|
|
1,066,219
|
|
July 1, 2010 July 31, 2010
|
|
|
|
|
|
|
|
|
|
|
433,781
|
|
|
|
1,066,219
|
|
August 1, 2010 August 31, 2010
|
|
|
|
|
|
|
|
|
|
|
433,781
|
|
|
|
1,066,219
|
|
September 1, 2010 September 30, 2010
|
|
|
99,559
|
|
|
|
14.61
|
|
|
|
533,340
|
|
|
|
966,660
|
|
October 1, 2010 October 31, 2010
|
|
|
72,900
|
|
|
|
15.02
|
|
|
|
606,240
|
|
|
|
893,760
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
606,240
|
|
|
$
|
13.19
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11.
|
Earnings
per Share (in thousands):
|
The following table sets forth the computation of basic and
diluted shares outstanding for the fiscal years ended October 31:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Numerator:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income from continuing operations
|
|
$
|
4,876
|
|
|
$
|
2,706
|
|
|
$
|
6,165
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator:
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator for basic earnings per share weighted
average common shares
|
|
|
11,262
|
|
|
|
11,588
|
|
|
|
12,395
|
|
Effect of dilutive securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares associated with option plans
|
|
|
179
|
|
|
|
239
|
|
|
|
326
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dilutive potential common shares
|
|
|
179
|
|
|
|
239
|
|
|
|
326
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator for diluted earnings per share weighted
average common shares and dilutive potential common shares
|
|
|
11,441
|
|
|
|
11,827
|
|
|
|
12,721
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options outstanding which were anti-dilutive totaled 827,
178 and 33 options for fiscal years ended October 31, 2010,
2009 and 2008, respectively.
48
SYNOVIS
LIFE TECHNOLOGIES, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
12.
|
Employee
Benefit Plan (in thousands):
|
Salary Reduction Plan: We sponsor a salary
reduction plan for all eligible U.S. employees who qualify
under Section 401(k) of the Internal Revenue Code.
Employees may contribute up to 100% of their annual
compensation, subject to annual limitations. At its discretion,
we may make matching contributions equal to a percentage of the
salary reduction or other discretionary amount for each plan. In
fiscal 2010, 2009 and 2008, we made discretionary matching
contributions to employee participants in the plan of $241, $164
and $131, respectively.
|
|
13.
|
Comprehensive
Income (in thousands):
|
The following table summarizes the components of comprehensive
income for the fiscal years ended October 31, 2010, 2009
and 2008.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Net income
|
|
$
|
4,876
|
|
|
$
|
2,706
|
|
|
$
|
11,485
|
|
Unrealized gain (loss) on investments
|
|
|
(66
|
)
|
|
|
70
|
|
|
|
22
|
|
Unrealized gain (loss) on ARS
|
|
|
|
|
|
|
2,429
|
|
|
|
(2,429
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other accumulated comprehensive gain (loss)
|
|
|
(66
|
)
|
|
|
2,499
|
|
|
|
(2,407
|
)
|
Comprehensive income
|
|
$
|
4,810
|
|
|
$
|
5,205
|
|
|
$
|
9,078
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14.
|
Quarterly
Information (in thousands except per share data):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
First
|
|
|
Second
|
|
|
Third
|
|
|
Fourth
|
|
Fiscal 2010 (unaudited)
|
|
Quarter
|
|
|
Quarter
|
|
|
Quarter
|
|
|
Quarter
|
|
|
Net revenue
|
|
$
|
15,212
|
|
|
$
|
17,600
|
|
|
$
|
17,637
|
|
|
$
|
18,116
|
|
Gross margin
|
|
|
10,852
|
|
|
|
12,862
|
|
|
|
12,736
|
|
|
|
13,090
|
|
Operating income
|
|
|
920
|
|
|
|
1,878
|
|
|
|
2,297
|
|
|
|
2,240
|
|
Net income
|
|
$
|
643
|
|
|
$
|
1,245
|
|
|
$
|
1,508
|
|
|
$
|
1,480
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per share:
|
|
$
|
0.06
|
|
|
$
|
0.11
|
|
|
$
|
0.13
|
|
|
$
|
0.13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share:
|
|
$
|
0.06
|
|
|
$
|
0.11
|
|
|
$
|
0.13
|
|
|
$
|
0.13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
First
|
|
|
Second
|
|
|
Third
|
|
|
Fourth
|
|
Fiscal 2009 (unaudited)
|
|
Quarter
|
|
|
Quarter
|
|
|
Quarter
|
|
|
Quarter
|
|
|
Net revenue
|
|
$
|
13,414
|
|
|
$
|
14,755
|
|
|
$
|
15,032
|
|
|
$
|
15,010
|
|
Gross margin
|
|
|
9,441
|
|
|
|
10,679
|
|
|
|
10,775
|
|
|
|
10,872
|
|
Operating income (loss)
|
|
|
2,240
|
|
|
|
2,774
|
|
|
|
(1,654
|
)
|
|
|
642
|
|
Net income (loss)
|
|
$
|
1,663
|
|
|
$
|
2,082
|
|
|
$
|
(4,874
|
)
|
|
$
|
3,835
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings (loss) per share:
|
|
$
|
0.14
|
|
|
$
|
0.18
|
|
|
$
|
(0.42
|
)
|
|
$
|
0.33
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings (loss) per share:
|
|
$
|
0.14
|
|
|
$
|
0.18
|
|
|
$
|
(0.42
|
)
|
|
$
|
0.33
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarterly calculations of net earnings per share are made
independently during the fiscal year.
49
|
|
Item 9
|
Changes
in and Disagreements with Accountants on Accounting and
Financial Disclosure
|
None.
|
|
Item 9A
|
Controls
and Procedures
|
As of the end of the period covered by this report, we conducted
an evaluation, under the supervision and with the participation
of our principal executive officer and principal financial
officer, of our disclosure controls and procedures (as defined
in
Rules 13a-15(e)
and
15d-15(e)
under the Securities Exchange Act of 1934 (the Exchange
Act)). Based on this evaluation, the principal executive
officer and principal financial officer have concluded that our
disclosure controls and procedures are effective and designed to
ensure that information required to be disclosed by us in
reports we file or submit under the Exchange Act is recorded,
processed, summarized and reported within the time periods
specified in Securities and Exchange Commission rules and forms.
There was no change in our internal control over financial
reporting during the most recently completed fiscal quarter that
has materially affected, or is reasonably likely to materially
affect, internal control over financial reporting.
Managements
Report on Internal Control Over Financial Reporting
Management is responsible for establishing and maintaining an
adequate system of internal control over financial reporting of
the Company. This system of internal accounting controls is
designed to provide reasonable assurance that assets are
safeguarded and transactions are properly recorded and executed
in accordance with managements authorization. The design,
monitoring and revision of the system of internal accounting
controls involves, among other things, managements
judgments with respect to the relative cost and expected
benefits of specific control measures. The effectiveness of the
control system is supported by the selection, retention and
training of qualified personnel and an organizational structure
that provides an appropriate division of responsibility and
formalized procedures. The system of internal accounting
controls is periodically reviewed and modified in response to
changing conditions. Designated Company employees regularly
monitor the adequacy and effectiveness of internal accounting
controls.
In addition to the system of internal accounting controls,
management maintains corporate policy guidelines that help
monitor proper overall business conduct, possible conflicts of
interest, compliance with laws and confidentiality of
proprietary information. The guidelines are documented in the
Synovis Code of Business Conduct and Ethics and are reviewed on
a periodic basis with all employees of the Company.
Because of its inherent limitations, a system of internal
control over financial reporting can provide only reasonable
assurance and may not prevent or detect misstatements. Further,
because of changes in conditions, effectiveness of internal
controls over financial reporting may vary over time. Our system
contains control monitoring mechanisms, and actions are taken to
correct deficiencies as they are identified.
Management conducted an evaluation of the effectiveness of the
system of internal control over financial reporting based on the
framework in Internal Control Integrated
Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO).
Based on this evaluation, management concluded that the
Companys system of internal control over financial
reporting was effective as of October 31, 2010. Grant
Thornton LLP, our independent registered public accounting firm,
has issued a report, included herein, on our internal control
over financial reporting.
|
|
ITEM 9B
|
Other
information
|
None.
50
PART III
|
|
Item 10
|
Directors,
Executive Officers and Corporate Governance
|
(a) Directors of the Registrant:
The information under the captions Election of
Directors Information About Nominees and
Election of Directors Other Information About
Nominees in the Registrants 2011 Proxy Statement is
incorporated herein by reference.
(b) Executive Officers of the Registrant:
Information concerning Executive Officers of the Company is
included under the caption Executive Officers of the
Registrant in Item 4A in this report.
(c) Compliance with Section 16(a) of the Exchange Act:
The information under the caption Section 16(a)
Beneficial Ownership Reporting Compliance in the
Registrants 2011 Proxy Statement is incorporated herein by
reference.
(d) Audit Committee and Audit Committee Financial Expert:
The information under the caption Election of
Directors Board Committees in the
Registrants 2011 Proxy Statement is incorporated herein by
reference.
(e) Code of Ethics:
We have adopted a Code of Ethics that applies to our Chief
Executive Officer and all senior financial officers. A copy of
the Code of Ethics has been posted on our website at
www.synovislife.com.
(f) Policy for Nominees:
The Companys policy for nominating Board candidates is
discussed under the caption Election of
Directors Board Committees in the
Registrants 2011 Proxy Statement and is incorporated
herein by reference. No material changes to the nominating
process have occurred.
|
|
Item 11
|
Executive
Compensation
|
The information under the captions Compensation Committee
Report, Director Compensation,
Compensation Discussion and Analysis and
Executive Compensation in the Registrants 2011
Proxy Statement is incorporated herein by reference.
|
|
Item 12
|
Security
Ownership of Certain Beneficial Owners and Management and
Related Stockholder Matters
|
Securities Authorized for Issuance Under Equity Compensation
Plans
51
EQUITY
COMPENSATION PLAN INFORMATION
The following table sets forth information as of
December 1, 2010 with respect to our compensation plans
under which equity securities are authorized for issuance.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
C
|
|
|
|
|
|
|
|
|
|
Number of
|
|
|
|
|
|
|
|
|
|
Securities
|
|
|
|
A
|
|
|
|
|
|
Remaining Available
|
|
|
|
Number of
|
|
|
|
|
|
for Future Issuance
|
|
|
|
Securities to be
|
|
|
B
|
|
|
Under Equity
|
|
|
|
Issued Upon
|
|
|
Weighted-Average
|
|
|
Compensation Plans
|
|
|
|
Exercise of
|
|
|
Exercise Price of
|
|
|
(Excluding
|
|
|
|
Outstanding
|
|
|
Outstanding
|
|
|
Securities
|
|
|
|
Options, Warrants
|
|
|
Options, Warrants
|
|
|
Reflected in Column
|
|
Plan Category
|
|
and Rights
|
|
|
and Rights
|
|
|
A)(1)
|
|
|
Equity compensation Plans approved by the Companys
shareholders
|
|
|
1,185,778
|
|
|
$
|
11.68
|
|
|
|
449,407
|
|
Equity compensation Plans not approved by the Companys
shareholders
|
|
|
|
|
|
$
|
|
|
|
|
|
|
Total
|
|
|
1,185,778
|
|
|
$
|
11.68
|
|
|
|
449,407
|
|
|
|
|
(1) |
|
Included in the securities remaining available for issuance
(Column C) are 347,886 shares associated with our 2006
Stock Incentive Plan and our prior 1995 Stock Incentive Plan and
101,521 shares associated with the Companys Employee
Stock Purchase Plan. The table does not include the proposed
additional shares to be reserved for issuance under the Employee
Stock Purchase Plan. |
Stock Ownership
The information under the caption Security Ownership of
Certain Beneficial Owners and Management in the
Registrants 2011 Proxy Statement is incorporated herein by
reference.
|
|
Item 13
|
Certain
Relationships and Related Transactions, and Director
Independence
|
The information under the captions Related Person
Relationships and Transactions, Election of
Directors Other Information About Nominees,
Election of Directors Director
Independence and Election of Directors
Board Committees in the Registrants 2011 Proxy
Statement is incorporated herein by reference.
|
|
Item 14
|
Principal
Accountant Fees and Services
|
(a) Audit Fees:
The information under the caption Fees of Independent
Auditors Audit Fees in the Registrants
2011 Proxy Statement is incorporated herein by reference.
(b) Audit-Related Fees:
The information under the caption Fees of Independent
Auditors Audit-Related Fees in the
Registrants 2011 Proxy Statement is incorporated herein by
reference.
(c) Tax Fees:
The information under the caption Fees of Independent
Auditors Tax Fees in the Registrants
2011 Proxy Statement is incorporated herein by reference.
(d) All Other Fees:
The information under the caption Fees of Independent
Auditors All Other Fees in the
Registrants 2011 Proxy Statement is incorporated herein by
reference.
(e) Fees of Independent Auditors Pre-Approval
Policies:
The information under the caption Fees of Independent
Auditors Pre-Approval Policies in the
Registrants 2011 Proxy Statement is incorporated herein by
reference.
52
PART IV
|
|
ITEM 15
|
Exhibits,
Financial Statement Schedule
|
(a) List of documents filed as part of this Report:
1) Financial Statements, Related Notes and Report of
Independent Registered Public Accounting Firm:
The following financial statements are included in this report
on the pages indicated:
|
|
|
|
|
|
|
Page
|
|
Reports of Grant Thornton LLP
|
|
|
28-29
|
|
Consolidated Statements of Income for the
years ended October 31, 2010, 2009 and 2008
|
|
|
30
|
|
Consolidated Balance Sheets as of
October 31, 2010 and 2009
|
|
|
31
|
|
Consolidated Statements of Shareholders
Equity for the years ended October 31, 2010, 2009 and 2008
|
|
|
32
|
|
Consolidated Statements of Cash Flows for the
years ended October 31, 2010, 2009 and 2008
|
|
|
33
|
|
Notes to Consolidated Financial Statements
|
|
|
34-49
|
|
2) Exhibits:
The exhibits to this Report on
Form 10-K
are listed in the Exhibit Index on pages
E-1 to
E-2 of this
Report.
The Company will furnish a copy of any exhibit to a shareholder
who requests a copy in writing to the Company. Requests should
be sent to: Chief Financial Officer, Synovis Life Technologies,
Inc., 2575 University Avenue W., St. Paul, Minnesota
55114-1024.
The following is a list of each management contract or
compensatory plan or arrangement required to be filed as an
exhibit to this Annual Report of
Form 10-K
pursuant to Item 15(b):
A. 1995 Stock Incentive Plan, as amended (incorporated by
reference to Exhibit 10.15 to the Companys Annual
Report on
Form 10-K
for the year ended October 31, 1998 (File No. 0-13907)).
B. Employee Stock Purchase Plan, as amended
December 10, 2009 (incorporated by reference to
Exhibit 10.1 to the Companys Quarterly Report on
Form 10-Q
for the period ended April 30, 2010 (File
No. 0-13907)).
C. Form of Change in control agreement dated
December 12, 2008 between
the
Company and Richard Kramp, Brett Reynolds, Michael Campbell,
Timothy Floeder, Mary Frick and Daniel Mooradian (incorporated
by reference to Exhibit 10.1 to the Companys Report
on
Form 8-K
dated December 17, 2008 (File
No. 0-13907)).
D. Summary of fiscal 2011 Non-Employee Director
Compensation (filed
herewith
electronically).
E. Summary of fiscal 2011 Named Executive Officer
Compensation (filed herewith electronically).
F. 2004 Non-Employee Director Stock Option Plan
(incorporated by reference to Exhibit 10.1 to the
Companys Report on
Form 10-Q
for the period ended April 30, 2004 (File
No. 0-13907)).
G. 2006 Stock Incentive Plan (incorporated by reference to
Exhibit 10.1 to the Companys Report on
Form 10-Q
for the period ended April 30, 2009 (File
No. 0-13907)).
53
H. Form of Incentive Stock Option Agreement under 2006
Stock Incentive Plan (incorporated by reference to
Exhibit 10.24 to the Companys Report on
Form 10-K
for the period ended October 31, 2006 (File
No. 0-13907)).
I. Form of Non-Statutory Stock Option Agreement under 2006
Stock Incentive Plan (incorporated by reference to Exhibit 10.25
to the Companys Report on
Form 10-K
for the period ended October 31, 2006 (File
No. 0-13907)).
(b) Exhibits:
The response to this portion of Item 15 is included as a
separate section of this Report on
Form 10-K
on pages E-1
to E-2.
54
SCHEDULE II
SYNOVIS
LIFE TECHNOLOGIES, INC.
VALUATION AND QUALIFYING ACCOUNTS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
|
|
Charged to
|
|
|
|
Balance
|
|
|
Beginning
|
|
Cost and
|
|
|
|
at End of
|
Description
|
|
of Period
|
|
Expenses
|
|
Deductions
|
|
Period
|
|
Allowance for doubtful accounts:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year ended October 31, 2010
|
|
$
|
344,000
|
|
|
$
|
204,000
|
|
|
$
|
145,000
|
|
|
$
|
403,000
|
|
Year ended October 31, 2009
|
|
|
270,000
|
|
|
|
149,000
|
|
|
|
75,000
|
|
|
|
344,000
|
|
Year ended October 31, 2008
|
|
|
173,000
|
|
|
|
133,000
|
|
|
|
36,000
|
|
|
|
270,000
|
|
55
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Synovis Life
Technologies, Inc.
Richard W. Kramp,
President and Chief Executive Officer
(Principal Executive Officer)
Dated: January 5, 2011
Pursuant to the requirements of the Securities Exchange Act of
1934, this report has been signed below on January 5, 2011
by the following persons on behalf of the registrant and in the
capacities indicated.
|
|
|
|
|
|
|
|
/s/ Richard
W. Kramp
Richard
W. Kramp
|
|
President, Chief Executive Officer and Director
(Principal Executive Officer)
|
|
|
|
/s/ Brett
A. Reynolds
Brett
A. Reynolds
|
|
Vice President of Finance, Chief Financial Officer
and Corporate Secretary
(Principal Financial and Accounting Officer)
|
|
|
|
/s/ John
D. Seaberg
John
D. Seaberg
|
|
Chairman, Board of Directors
|
|
|
|
/s/ William
G. Kobi
William
G. Kobi
|
|
Director
|
|
|
|
/s/ Karen
Gilles Larson
Karen
Gilles Larson
|
|
Director
|
|
|
|
/s/ Mark
F. Palma
Mark
F. Palma
|
|
Director
|
|
|
|
/s/ Richard
W. Perkins
Richard
W. Perkins
|
|
Director
|
|
|
|
/s/ Timothy
M. Scanlan
Timothy
M. Scanlan
|
|
Director
|
|
|
|
/s/ Sven
A. Wehrwein
Sven
A. Wehrwein
|
|
Director
|
56
SYNOVIS
LIFE TECHNOLOGIES, INC.
EXHIBIT INDEX
TO ANNUAL REPORT ON
FORM 10-K
For the
Year Ended October 31, 2010
|
|
|
|
|
|
2
|
.1
|
|
Asset Purchase Agreement among Heraeus Vadnais, Inc., Heraeus
Materials Caribe, Inc., and Heraeus Materials S.A., as Buyers,
and Synovis Interventional Solutions, Inc., Synovis Caribe, Inc.
and Synovis Life Technologies, Inc., as Seller Parties, dated as
of January 8, 2008 (incorporated by reference to Exhibit 10.1 to
the Companys Report on Form 8-K dated January 8, 2008
(File No. 0-13907)).
|
|
2
|
.2
|
|
Foreclosure Sale Agreement by and between Comerica Bank and
Synovis Surgical Sales, Inc., a wholly-owned subsidiary of
Synovis Life Technologies, Inc., dated as of July 2, 2009
(incorporated by reference to Exhibit 2.1 to the
registrants Current Report on Form 8-K dated
July 2, 2009 (File No. 0-13907)) (Schedules and Exhibits
have been omitted; however copies thereof will be furnished to
the Securities and Exchange Commission upon request).
|
|
3
|
.1
|
|
Restated Articles of Incorporation of the Company, as amended,
(incorporated by reference to Exhibit 3.1 to the
Companys Quarterly Report on Form 10-Q for the
quarter ended April 30, 1997 (File No. 0-13907)).
|
|
3
|
.2
|
|
Amendment to Restated Articles of Incorporation of the Company,
as amended, dated March 20, 1997 (incorporated by reference
to Exhibit 3.2 to the Companys Quarterly Report on
Form 10-Q for the quarter ended April 30, 1997 (File
No. 0-13907)).
|
|
3
|
.3
|
|
Amended and Restated Bylaws of the Company (incorporated by
reference to Exhibit 3.1 to Form 8-K filed on
October 5, 2007 (File No. 0-13907)).
|
|
3
|
.4
|
|
Amendment to Restated Articles of Incorporation, effective
May 1, 2002, regarding the Company name Change from
Bio-Vascular, Inc. to Synovis Life
Technologies, Inc. (incorporated by reference to
Exhibit 3.1 to the Companys Quarterly Report on
Form 10-Q for the quarter ended April 30, 2002 (File
No. 0-13907)).
|
|
4
|
.1
|
|
Form of common stock Certificate of the Company (incorporated by
reference to Exhibit 4.1 to the Companys registration
statement on Form 10 (File No. 0-13907)).
|
|
4
|
.2
|
|
Rights Agreement, dated as of June 1, 2006, between Synovis
Life Technologies, Inc. and American Stock Transfer & Trust
Company, as Rights Agent, including exhibits thereto
(incorporated by reference to Exhibit 4.1 to the
Companys Registration Statement on Form 8-A dated
June 1, 2006 (File No. 0-13907)).
|
|
4
|
.3
|
|
Restated Articles of Incorporation of the Company, as amended
(see Exhibit 3.1).
|
|
4
|
.4
|
|
Amendment to Restated Articles of Incorporation of the Company,
as amended, dated March 20, 1997 (see Exhibit 3.2).
|
|
4
|
.5
|
|
Amended and Restated Bylaws of the Company (see Exhibit 3.3).
|
|
4
|
.6
|
|
Amendment to Restated Articles of Incorporation, effective
May 1, 2002 (see Exhibit 3.4).
|
|
10
|
.1
|
|
1995 Stock Incentive Plan, as amended (incorporated by reference
to Exhibit 10.15 to the Companys Annual Report of
Form 10-K for the year ended October 31, 1998 (File
No. 0-13907)).
|
|
10
|
.2
|
|
Employee Stock Purchase Plan, as amended December 10, 2009
(incorporated by reference to Exhibit 10.1 to the Companys
Quarterly Report on Form 10-Q for the period ended April 30,
2010 (File No. 0- 13907)).
|
|
10
|
.3
|
|
Change in control agreement dated December 12, 2008 between
the Company and Richard Kramp, Brett Reynolds, Michael
Campbell, Timothy Floeder, Mary Frick and Daniel Mooradian
(incorporated by reference to Exhibit 10.1 to the Companys
Report on Form 8-K dated December 17, 2008
(File No. 0-13907)).
|
|
10
|
.4
|
|
Acquisition Agreement and Plan of Reorganization by and among
the Company, MCA Acquisition, Inc., Medical Companies Alliance,
Inc. and Michael K. Campbell, dated July 6, 2001
(incorporated by reference to Exhibit 10.1 to the
Companys Quarterly Report on Form 10-Q for the period
ended July 31, 2001 (File No. 0-13907)).
|
|
10
|
.5
|
|
Lease Agreement effective August 1, 1995 between the
Company and CSM Investors, Inc. (incorporated by reference to
Exhibit 10.25 to the Companys Annual Report on
Form 10-K for the year ended October 31, 1995 (File
No. 0-13907)).
|
E-1
|
|
|
|
|
|
10
|
.6
|
|
First Amendment to Lease Agreement effective August 1, 1995
between the Company and CSM Investors, Inc., dated
September 19, 2002 (incorporated by reference to
Exhibit 10.14 to the Companys Annual Report on
Form 10-K for the period ended October 31, 2002 (File
No. 0-13907)).
|
|
10
|
.7
|
|
Second Amendment to Lease Agreement effective August 1,
1995 between the Company and CSM Investors, Inc., dated
January 1, 2004 (incorporated by reference to
Exhibit 10.7 to the Companys Annual Report on
Form 10-K for the period ended October 31, 2008 (File
No. 0-13907)).
|
|
10
|
.8
|
|
Third Amendment to Lease Agreement effective August 1, 1995
between the Company and CSM Investors, Inc., dated
August 1, 2005 (incorporated by reference to
Exhibit 10.14 to the Companys Annual Report in
Form 10-K for the period ended October 31, 2005 (file
No. 0-13907)).
|
|
10
|
.9
|
|
2004 Non-Employee Director Stock Option Plan (incorporated by
reference to Exhibit 10.1 to the Companys Report on
Form 10-Q for the period ended April 30, 2004 (File
No. 0-13907)).
|
|
10
|
.10
|
|
Summary of fiscal 2011 Non-Employee Director Compensation (filed
herewith electronically).
|
|
10
|
.11
|
|
Summary of fiscal 2011 Named Executive Officer Compensation
(filed herewith electronically).
|
|
10
|
.12
|
|
2006 Stock Incentive Plan (incorporated by reference to Exhibit
10.1 to the Companys Quarterly Report on Form 10-Q for the
quarter ended April 30, 2009 (File No. 0-13907)).
|
|
10
|
.13
|
|
Form of Incentive Stock Option Agreement under 2006 Stock
Incentive Plan (incorporated by reference to Exhibit 10.24
to the Companys Annual Report on Form 10-K for the
period ended October 31, 2006 (File No. 0-13907)).
|
|
10
|
.14
|
|
Form of Non-Statutory Stock Option Agreement under 2006 Stock
Incentive Plan (incorporated by reference to Exhibit 10.25
to the Companys Annual Report on Form 10-K for the period
ended October 31, 2006 (File No. 0-13907)).
|
|
10
|
.15
|
|
Fourth Amendment to Lease Agreement effective August 1,
1995 between Company and CSM Investors, Inc., dated
August 4, 2008 (incorporated by reference to
Exhibit 10.1 to the Companys Report on Form 8-K
dated August 5, 2008 (File No. 0-13907)).
|
|
10
|
.16
|
|
Lease agreement effective July 17, 2009 between the Company
and the Irvine Company LLC (incorporated by reference to
Exhibit 10.25 to the Companys Annual Report on Form
10-K for the period ended October 31, 2009 (File No.
0-13907)).
|
|
21
|
.1
|
|
List of Subsidiaries of the Company (filed herewith
electronically).
|
|
23
|
.1
|
|
Consent of Grant Thornton LLP (filed herewith electronically).
|
|
31
|
.1
|
|
Certification of Chief Executive Officer pursuant to
Rule 13a-14(a) of the Securities Exchange Act of 1934
(filed herewith electronically).
|
|
31
|
.2
|
|
Certification of Chief Financial Officer pursuant to
Rule 13a-14(a) of the Securities Exchange Act of 1934
(filed herewith electronically).
|
|
32
|
.1
|
|
Certification pursuant to 18 U.S.C. Section 1350 as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed
herewith electronically).
|
E-2